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RHEUMATOID ARTHRITIS 
Aetiology, pathogenesis and clinical aspects of the disease  
Rheumatoid arthritis (RA) is a common, chronic autoimmune disease characterized by synovial inflammation 
and hyperplasia, which, if left untreated, results in cartilage destruction, joint space narrowing, bone erosion 
and periarticular demineralization (Figure 1). Other features of RA include autoantibody production, pain and 
long-term disability [1]. Although the disease primarily affects joints, it can also result in a variety of extra-
articular manifestations, including cardiovascular (myocardial infarction, cerebrovascular events and heart 
failure), pulmonary (inflammatory and fibrotic disease), hepatic, psychological (fatigue and reduced cognitive 
function) and skeletal (osteoporosis) symptoms. With the peak of onset in the fourth and fifth decade of life, 
RA impacts heavily on people of working age and imposes a substantial economic burden on society [2]. 
More importantly, RA is found to be associated with increased comorbidity and reduces life span of patients 
by 3-10 years [3].  
 
Figure1. Schematic presentation of healthy (left) and arthritic (right) joint 
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The prevalence of RA is estimated to be 0.5-1% in European and North American populations [4]. Lower rates 
are seen in Asians and Africans, and substantially higher prevalence is noted in North American Native 
populations, with estimates as high as 5.3% in Pima Indians [5-7]. There is also disproportionality in 
prevalence ratios, disease severity and treatment response between males and females affected with RA [8-
13]. The prevalence of RA is two- to threefold higher in women than men, and although disease severity is 
similar in both genders at the time of diagnosis, men are more likely to achieve sustained remission in early 
RA [12]. In the case of established disease, however, gender seems to play no role in achieving sustained 
remission [12, 14]. Furthermore, several studies have suggested that males also have a better response to 
therapy [10, 11, 15]. Surprisingly, some evidence also suggests that severity and incidence of RA might be 
in decline, with onset happening later in life [16-18]. This geographic, temporal and gender variability 
observed in RA indicates that a combination of environmental exposures and genetic factors play a role in 
development and progression of the disease. Indeed, epidemiological research spanning several decades 
established RA as a multifactorial disorder [4].    
RA exhibits extensive phenotypic heterogeneity in both presentation of the symptoms and treatment response. 
In about 60% of the cases, weight loss, fatigue, stiffness and low-grade fever are symptoms preceding full-
blown synovitis. Joint inflammation usually first affects the smaller joints of hands and feet, leading to pain, 
warmth, tenderness and swelling. As the disease progresses, symptoms often spread to the knees, ankles, 
elbows, hips and shoulders. In most cases, the inflammation is symmetrical, involving the same joints on 
both sides of the body. In a majority of RA patients the disease activity is persistent but fluctuating; with 
periods of increased disease activity, called flares, alternating with periods of low disease activity [19].   
The first description of RA recognized by modern medicine appeared in the late 17th century in the 
dissertation of the Augustin Jacob Landé-Beauvais [20]. The disease was definitely distinguished from gout 
and rheumatic fever by Archibald Garrod, who coined the term “Rheumatoid Arthritis” in the year 1890 [21]. 
From these initial definitions of the disease, a set of current disease classification criteria was designed by 
the American College of Rheumatism (ACR) in the 1980s to distinguish established RA from other types of 
joint diseases (Figure 2) [22]. A patient is classified as having rheumatoid arthritis if he/she satisfies at least 
four out of seven criteria, where the first four criteria need to be present for at least 6 weeks. Although the 
criteria set is in widespread international use and served well in providing a benchmark for disease definition, 
it is limited by poor sensitivity and specificity in identifying patients with early inflammatory arthritis that will 
later on develop RA [23]. Since it has been recognized that early therapeutic intervention in RA results in 
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greater improvement of clinical outcomes, the window of opportunity to receive treatment that could control 
disease activity and prevent structural damage might already have passed for many of the patients classified 
as having RA using 1987 ACR criteria [24-26]. For this reason, the ACR and European League Against 
Rheumatism (EULAR) devised new classification criteria for early RA (Figure 2).  
With the marked differences in disease presentation both within and between the patients, it is becoming 
increasingly evident that RA should be considered as a clinical syndrome that spans several disease subsets 
with different inflammatory cascades, rather than a discrete patho-physiological entity [28]. Two distinct 
subsets of patients are classified on the basis of the presence of antibodies to citrullinated protein antigen 
(ACPA), which are found in approximately 70% of the RA patients [29]. The presence of ACPA antibodies can 
precede the clinical manifestations of RA by many years and is predictive for development of early RA [30]. 
Moreover, they can serve as an informative prognostic marker, since joint destruction, comorbidities and 
other extra-articular manifestations of the disease are more prominent in ACPA seropositive patients [31, 32].    
 
 
 
 
 
 
Figure 2. Overview of the 1987 and the 2010 ACR/EULAR criteria. Adapted from Scott et al [27]. 
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Box 1| Genome-wide association studies (GWAS). 
GWAS have become the most powerful and 
extensively utilized approach in discovering 
susceptibility variants for complex traits. High-
throughput SNP genotyping technologies have 
allowed researchers to genotype a large amount of 
common variation, while the completion of the 
Human Genome Project in 2001 [39] and the initial 
release of the International Hap Map project in 2003 
[40] paved the way forward for this approach, 
allowing the design of genotyping arrays to capture 
variation across the entire genome. The coverage of 
SNP genotyping arrays, however, is limited, so the 
underlying rationale for GWAS is the common 
disease common variant hypothesis (CDCV) [41]. 
This proposes that common disease alleles (SNPs) 
with minor allele frequency (MAF) less than 1% 
underlie most common traits [42]. Another caveat for 
these studies is the issue of multiple testing, as they 
asses variation across a large number of loci, and 
typically require a very high level of significance to 
convincingly demonstrate a significant association 
(P<5x10-8). To achieve this level of statistical 
significance large collections of samples are needed, 
even when the effect of the risk variant is expected to 
be high. The success and popularity of this strategy 
has been evidenced by an online catalog which 
contained 13,661 published GWAS for 1,521 
different complex traits as of June 2013, and is still 
growing [43].  
Genetics of RA  
Despite enormous efforts, the complete etiological 
picture of RA remains unclear. The first evidence 
supporting genetic predisposition to RA came from 
twin and sibling studies, which have estimated the 
relative contribution of genetic factors to the disease 
to be 50-60%, leaving the remaining part to 
environment and stochastic factors [33-35]. Despite 
the fact that studies implicated many environmental 
factors as risk factors for development of RA, 
including hormones, pollution, infectious agents and 
diet, smoking remains the only validated 
environmental risk factor associated with onset of 
seropositive RA  [36-39]. [40-44] 
Research spanning several decades accumulated 
substantial evidence of a genetic basis of RA through 
the identification of genetic susceptibility variants.  
Different strategies have been effectively utilized to 
identify RA susceptibility loci, and they can be broadly 
divided to: unbiased genome-wide investigations, 
including linkage analysis and genome-wide 
association studies (GWAS) (Box 1) and targeted 
investigations of variation in candidate genes, which 
are expected to play a role in the pathophysiology of 
RA based on the prior knowledge. 
The HLA region is the largest contributor to the genetic 
variation in RA. The first association of certain HLA 
D/DR alleles and risk of RA was reported in 1970s 
[45]. Over time this finding evolved to include 
association of several distinct alleles of HLA-DRB1 
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gene. It was recognized that these alleles share a common motive, termed shared epitope (SE), which codes 
for a consensus amino acid sequences spanning positions 70-74 in the β1 subunit of the HLA-DR molecule 
[46]. SE alleles have been consistently associated with RA in many populations, and estimates of genetic 
variability of RA explained by this locus have ranged from 18-37% [47, 48]. However, the SE hypothesis does 
not fully explain the association at the locus, with several studies suggesting additional independent 
associations within the MHC [49-51]. Recent findings indeed indicate that three amino acid positions in 
HLA-DRβ1 (11, 71 and 74), together with single-amino-acid polymorphisms in HLA-B (position 9) and HLA-
DPβ1 (position 9), almost completely explain the MHC association to risk of RA [52]. The PTPN22 gene, 
coding for a tyrosin phosphatase, was the second confirmed locus discovered in the pre-GWAS era. The first 
association of RA susceptibility with the minor allele of a missense SNP in PTPN22 was reported in a study of 
87 putative functional SNPs in RA candidate genes and/or linkage regions [53]; and this association was 
consistently validated with RA risk in populations of European descent [53-55]. The association of STAT4, 
coding for a transcription factor involved in cytokine receptor signaling, with increased RA risk was identified 
with a combination of candidate gene and linkage studies. Although confirmed in all studied populations to 
date, the association of STAT4 with RA risk is considerably more modest than those reported for HLA-DRB1 
and PTPN22 [56-59].    
GWAS have become the most fruitful approach in discovering susceptibility variants for RA, bringing the total 
number of confirmed RA risk loci up to ~60 [60-62]. Although GWAS have provided a valuable insight into 
the genetic basis of RA, the identified associations in most cases have a modest effect size with odds ratios 
(OR) <1.5. Besides, published SNPs account for only a fraction of the genetic heritability of the disease. This 
gap between variance associated with DNA variants identified in GWASs versus twin study heritability is often 
referred to as “missing heritability”, and can be explained in several ways. Simulation and empirical analysis 
of GWA data in RA demonstrate that additional common alleles of small effect sizes remain to be discovered, 
and growing international collaboration and enlarging patient sample collections will certainly further enhance 
these discoveries [63]. The fraction of “missing heritability” might also be due to rare and structural variants, 
including copy number variants (CNVs), which are poorly covered in current genotyping assays. Recent 
large-scale human sequencing studies reported an abundance of rare variants (variants with minor allele 
frequency (MAF) < 0.5%) within exons with likely deleterious effects [64, 65]; moreover, a vast majority 
(~95%) of identified exonic variants were found to be rare. These findings are suggesting that rare variants 
with modest to high effect are a likely cause of a substantial fraction of unexplained heritability. However, only 
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a few examples of rare, coding variants associated with common autoimmune diseases have been reported so 
far [66-71], with recent publication taking the view that rare variants have a negligible impact on the variance 
in complex traits [72]. Nevertheless, all of the sequencing studies reported in the field of auto-immune 
disease to date sequenced only a selection of candidate genes, thereby neglecting the rest of the variation 
through genome. Moreover, sample sizes used in these studies were underpowered to detect anything but 
associations of rare variants with large effect sizes; so that the question of to what extent rare variants explain 
complex disease etiology remains open. Variation in copy number of DNA segments in the human genome 
represents a significant source of genetic and phenotypic variation in human populations [73-76], still 
comprehensive studies of the contribution of these variants to RA susceptibility are generally lacking. This is 
partly due to the lack of reliable assays for CNV detection but recent technical and analytical developments 
allowed the active pursuit in recent years. Several association studies implicated the role of common CNVs 
found in RA candidate genes in the susceptibility of the disease [77-80] and a result of the Welcome Trust 
Case Control Consortium (WTCCC) genome-wide study indicated the involvement of common CNVs in the 
HLA region and 11 rare CNV regions in RA susceptibility [81, 82]. Nevertheless, studies examining the role of 
these variants in disease susceptibility are still lagging behind in size and numbers as compared to the 
studies focusing on SNPs.  
The majority of the genetic risk factors for RA identified to date have been found in seropositive (rheumatoid 
factor and/or ACPA-positive) samples. The difference in genetic background of these two subsets of RA 
patients is most evident in the role of the SE alleles in disease predisposition for ACPA-positive and ACPA-
negative RA patients [47, 83]. While in seropositive disease, SE alleles confer the strongest risk factor; their 
contribution to the seronegative disease seems to be much more modest, if existing at all.   
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TREATMENT OF RA 
There is no definitive cure for RA, and modern treatment strategies are aimed at reducing inflammation and 
halting erosive damage. However, new insights into the treatment of RA strongly improved the outcomes in 
RA and clinical remission has become an achievable goal for many patients [84, 85]. Findings of several 
studies have demonstrated that early, aggressive treatment, coupled with good surveillance and rapid 
adjustment of the therapy to achieve tight disease control, results in superior clinical outcomes, with 55-68% 
of tight-control patients resulting in remission after one year versus 30% of usual care patients [86-90]. 
Although the ultimate goal of treatment is disease remission, the perception of patients' health status and 
need for care differ between physicians and patients [91-93]. Pain has been explicitly and consistently 
reported by RA patients as their preferred area for improvement and the highest priority in treatment [94-96]. 
However, pain persists in a large proportion of the RA patients, even when the inflammation has been 
adequately controlled and patients classified as achieving remission according to DAS28 criteria [97].  
Current treatment for new patients is usually started with methotrexate (MTX), the cornerstone drug for RA. 
MTX is administered weekly to achieve maximum response within 3-6 months, with a recommendation of 
close monitoring of the disease progression during this period [98-100]. If patients show insufficient 
response and/or adverse events, MTX can be replaced by another disease modifying anti-rheumatic drug 
(DMARD) or a second DMARD can be added to MTX. Nevertheless, about 30-40% of the patients show 
unsatisfactory response to synthetic DMARDs, and the usual next step is to switch to a biologically-derived 
drug, which can be prescribed as monotherapy but it is usually prescribed in combination with another 
DMARD. 
A major key to advances in management of RA has been the development of valid and standardized 
instruments that evaluate the disease progression and activity. Considering the variability of disease 
expression and heterogeneity seen in RA, the construction of such disease activity measures is no easy task. 
The key outcomes in RA are persistent joint inflammation, progressive joint damage and functional decline 
[101]; but other important outcomes include extra-articular manifestations, comorbidities and patient-related 
factors, such as fatigue and pain. Several core measurements are used to asses these disease outcomes and 
they can be broadly divided into laboratory, doctor and patient based measurements. Laboratory measures 
entail erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), or both. Physician-based reviews 
include swollen and tender joint counts (SJC and TJC) and global assessment (physician estimate of disease 
activity recorded on the visual analogue scale, VASGH); with standard joint counts focusing on 28 joints in 
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the hands, upper limbs and knees; whereas, patient-based measures evaluate pain, global assessment and 
disability. A number of combined indices that aggregate these individual assessments have been developed, 
and are widely used in both clinical trials and observational studies. A well standardized and validated 
instrument for assessing disease activity in RA is Disease Activity Score 28 (DAS28) [102-105]. The DAS28 
is calculated using a mathematical formula comprising the number of SJC and TJC (out of 28 specified 
joints), the patients‟ assessment of global health (visual analogue scale, VASGH) and laboratory markers of 
inflammation (ESR or CRP) (Figure 3).  
 
 
 
Figure 3. DAS28 formula. The parameters included in the calculation are: tender joint count (TJC28), swollen 
joint count (SJC28), erythrocyte sedimentation rate (ESR) and the patient's assessment of global general 
health (VASGH).   
 
 
 
DAS28 greater than 5.1 is indicating active disease, less than 3.2 well controlled disease and less than 2.6 
remission. To measure individual treatment response in RA patients, the DAS-based European League 
Against Rheumatism (EULAR) response criteria were developed. These criteria use the individual change in 
DAS28 and the level of DAS reached as a consequence of treatment to classify patients as good, moderate or 
non-responders (Table 1) [106].    
Besides disease activity, the precise and reproducible quantification of the progression of the destruction of 
cartilage and the erosion in the underlying bone caused by RA is also crucial to monitor severity and clinical 
course of the disease. Although modern technologies, including magnetic resonance imaging (MRI) and 
ultrasound, are more sensitive in distinguishing early structural changes in joints, plain radiographs still 
remain the most widespread imaging technique, due to availability and low cost [107]. 
  
 
DAS28 = 0.56 x √(TJC28) + 0.28 x √(SJC28) + 0.70 x lognat (ESR) + 0.014 x VASGH 
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Table 1. EULAR response criteria 
DAS28 at endpoint Improvement in DAS28 from baseline 
 > 1.2 > 0.6 and ≤ 1.2 ≤ 0.6 
≤ 3.2 Good   
> 3.2 and ≤ 5.1  Moderate  
> 5.1   None 
    
 
 
 
Several methods have been introduced for the scoring of radiological damage, of which the two most widely 
applied instruments are the Sharp's score and Larsen's method [108-110]. However, these methods are 
associated with several limitations such as limited generalizability and objectivity, due to high intra- and 
inter-reader variability. To overcome this impediment, a lot of effort is being made to enable automation and 
computer-aided methods for scoring [111, 112].  
 
TNF and its role in the pathology and treatment of RA 
In contrast to the painfully slow advances in understanding the cause of RA, major progress has been made in 
our understanding of the pathological progress that takes place during the course of the disease. A number of 
cytokines, chemokines and growth factors involved in the maintenance of the chronic inflammation in RA 
have been identified [113]. TNF-α plays a crucial role in the pathogenesis of RA through activation of the 
inflammatory cascade. This cytokine, produced primarily by macrophages, and to a lesser extent 
lymphocytes, is involved in activation of chemokine and cytokine expression, expression of endothelial-cell 
adhesion molecules and promotion of angiogenesis, protection of synovial fibroblasts, suppression of 
regulatory T cells and introduction of pain [114, 115]. The importance of TNF-α in the pathogenesis of RA 
was postulated from observations in animal models and cultured synovial cells [116-121], but definitive 
confirmation of its role in human RA came from clinical trials which proved TNF neutralizing approaches to be 
highly effective in reducing disease activity and radiographic progression of disease [122-126].  
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Five anti-TNF agents are currently commercially available for the treatment of RA, three of which are full 
length monoclonal antibodies: infliximab, adalimumab and golimumab. Infliximab (Remicade®) is a chimeric 
IgG1κ monoclonal antibody composed of human constant and murine variable regions. Adalimumab 
(Humira®) and golimumab (Simponi®) are fully human IgG1 antibodies, produced using recombinant DNA 
technology. Etanercept (Enbrel® ) is a dimeric fusion protein consisting of the extracellular ligand-binding 
portion of the human 75 kDac (p75) receptor of TNF, linked to the Fc portion of human IgG1. Certolizumab 
pegol (Cimzia®) is a recombinant, humanized antibody Fab fragment, specific for human TNF, conjugated to 
polyethylene glycol (PEG). The absence of an Fc fragment prevents effector function such as complement-
dependent lysis and antibody-dependent cell-mediated cytotoxicity (ADCC) [127]. According to regulations 
in the Netherlands, TNF-blocking agents are prescribed to the RA patients if their DAS28 score is higher than 
3.2 at baseline and they failed to respond to therapy with at least two synthetic DMARDs [128].  
The neutralization of TNF has proven to be an effective and well-tolerated therapy, with most of the treated 
patients responding favourably [129-131], but at the same time, the response rate varies, with approximately 
30-40% of cases failing to achieve a long-lasting response [132-134]. Essentially, two distinct types of non-
response can be identified: a primary non-response, which is evident early in the course of the therapy and 
secondary non-response, that develops over time in the initial responders because of an acquired drug 
resistance [135-139]. Equally important, treatment with TNF inhibitors is accompanied by adverse events 
which can lead to therapy discontinuation. Adverse drug reactions reported during anti-TNF therapy include 
common, minor events, such as infusion reactions, but also more serious complications being increased 
susceptibility to tuberculosis and other concomitant infections, melanoma and neutropenia [140-143]. The 
mechanism underlying response failures is not fully understood, but it possibly includes drug bioavailability, 
pharmacokinetics, pharmacodynamics and/or immunogenicity [144]. In fact, the circulating levels of the drug 
have been found to vary significantly among patients [145], which could in theory be a useful marker for 
adjusting the treatment intensity and dosing. An even more critical issue seems to be the immunogenicity of 
these drugs, with anti-drug antibodies (ADAs) against TNF inhibitors being found for all five available agents 
[145-152]. ADAs against TNF inhibitors have been associated with a low level of active drug, treatment 
response and induction of adverse events [145, 148, 153-157]. However, ADAs are not detected in all 
patients with treatment failure, indicating that non-response is a more heterogeneous and complex process 
caused only partly by ADAs [155, 158].       
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It is to be expected that inter-individual variability in drug response is a multifactorial event, influenced by 
both genetic and environmental factors [159, 160]. Several biomarkers, clinical parameters and 
environmental influences have already been found to be associated with the response to TNF inhibitors, 
including concurrent use of DMARDs, lower baseline Health Assessment Questionnaire score, gender, 
smoking, serological status, TNF levels at the site of inflammation, and the synovial microarchitecture. 
Nevertheless, these explain only a relatively small proportion of the observed variance in response (17–29%) 
[161-164]. These observations, together with high costs and a narrow therapeutic window for application of 
TNF inhibitors, have led the search for genetic markers that could predict different response profiles.  
 
PHARMACOGENETICS 
As more drug therapies are used to manage diseases, it is increasingly apparent that most drugs and drug 
dosages do not have uniform effects across patients. Drug therapy can be impacted by many variables, such 
as age, organ function, or drug-drug interactions; however, there is mounting evidence that an individual's 
genome is a dominant factor. It is estimated that genetic variation can account for 15-95% of variability of 
drug effects observed between the patients [165-167]. Pharmacogenetics is the study of the role of inherited 
and acquired genetic variation in individual responses to drugs, both in terms of therapeutic effect and 
adverse events, with the promise of tailoring the therapy to the individual patient (Figure 4).  
Still pharmacogenetics as a discipline has relevance beyond predicting efficacy and toxicity in a clinical 
setting, as genetic markers can indicate novel drug targets on one hand and serve to identify disease subsets 
on the other. The elucidation of the genetic base for inherited differences in drug response began in the late 
1980s, with initial studies on the polymorphic human gene encoding the drug metabolizing enzyme 
cytochrome P450 2D6 (CYP2D6) [168]. Other similar clinically relevant pharmacogenetic examples, mainly 
involving genes involved in drug metabolism or mechanism of action, have been known for decades; 
however, recently, the field of pharmacogenetics have evolved into "pharmacogenomics", involving a shift of 
a focus from individual candidate genes to genome wide association studies. Single nucleotide 
polymorphisms (SNPs) represent the most abundant form of genetic variation in humans, constituting ~90% 
of all our genome variation and occurring every 100-300 nucleotides. It is estimated that there are 
approximately 7 million SNPs in human genome of which the minor allele frequency is >5% [169]. Most 
SNPs are thought to have no phenotypic effect, however some of these genetic variances are proven to have 
an effect on drug metabolizing enzymes, transporters, receptors and signaling pathways in altering drug 
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response [165, 170, 171]. Nevertheless, the importance of rare variants is increasingly being recognized 
[172]. Early progress in pharmacogenetics came from small candidate-gene studies which investigated 
genes encoding drug-metabolizing enzymes, drug receptors, transporters and drug targets [173]. In case of 
pharmacogenetic studies of response to TNFi therapy, studies of candidate genes focused on genes involved 
in the TNF signaling pathway (primarily TNFA, encoding TNF cytokine) and genes known to be involved in RA 
pathogenesis [174]. A big drawback of this approach is its reliance on a priori knowledge about the 
pharmacology of the medication. To compensate for this disadvantage, broad, hypothesis-free approaches 
may be better suited for pharmacogenomic studies, especially when the genetic architecture of treatment 
response is expected to be complex, as is the case with TNF inhibiting agents [160].   
 
 
 
  
Figure 4. Pharmacogenetics has the potential to identify the subset of patients who are genetically 
predisposed not to respond to specific therapy or develop side effects. Individual variation in drug response is 
the result of a combination of genetic and environmental factors. BMI, body mass index. 
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AIM AND OUTLINE OF THE THESIS 
 
The studies included in this thesis aimed at identifying genetic predictors of response to anti-TNF treatment 
in patients with RA and exploring the role of CNVs in the onset of the disease. In the context of personalized 
medicine, genetic research holds a promise of tailoring the treatment to the individual patient but also 
indicate novel drug targets through better understanding of biological pathways involved in the pathogenesis.  
The first part of the thesis, described in chapter 2, focuses on the analysis of the association of the deletion of 
the late cornified envelope genes LCE3B and LCE3C (LCE3C_LCE3B-del) with onset of RA. LCE3C_LCE3B-
del is a known risk factor for psoriasis, and studies in Spanish and Chinese population indicated an 
association of this deletion with risk of developing RA. We aimed to replicate these findings in the Dutch 
population. 
The second part of the thesis, including chapters 3 to 6, employs a non-hypothesis driven genome-wide 
association approach in analysis of the pharmacogenetics of the TNFi response in patients with RA. 
Chapter 3 provides an overview of the current literature regarding the pharmacogenetics of DMARDs in 
patients with RA, including TNFi therapy. Different strategies and perspectives for further studies are also 
discussed. 
In chapters 4-6 genome-wide association studies are performed with over 2 million common genetic variants 
tested for association with the phenotype, without a priori knowledge about the effect of the variant. In these 
GWAS several different aspects of treatment outcome were investigated.  
A multi-stage GWAS on TNFi therapy response in patients with RA is presented in chapter 4. The outcome of 
the TNFi therapy used in analysis was a change in DAS28 after 14 weeks of treatment.  
In chapter 5, the change in pain after fourteen weeks of the TNFi treatment in RA patients was utilized as an 
alternative outcome in a GWAS meta-analysis of four populations with European descent.  
Chapter 6 focuses on the analysis of DAS28 and its separate components, in an attempt to define the most 
optimal outcome for the future studies of the TNFi response in patients with RA.  
 
Finally, the findings described in this thesis are summarized and the future research perspectives in genetics 
and pharmacogenetics of RA are discussed in chapter 7.    
  
28 
  
29 
 
 
 
 
 
 
 
 
 
Chapter 2 
A REPLICATION STUDY OF THE ASSOCIATION BETWEEN RHEUMATOID 
ARTHRITIS AND THE DELETION OF THE LATE CORNIFIED ENVELOPE 
GENES LCE3B AND LCE3C 
 
Judith GM Bergboer, Maša Umićević Mirkov, Jaap Fransen, Martin den Heijer, Barbara 
Franke, Piet LCM van Riel, Joost Schalkwijk, Marieke JH Coenen 
 
 
 
 
 
 
 
 
 
 
PLoS ONE (2012) 7:e32045 
  
30 
 
  
31 
Abstract  
Introduction: Two recent studies, in a Spanish and a Chinese population, point to an association between 
rheumatoid arthritis (RA) risk and the deletion of the Late Cornified Envelope (LCE) 3B and 3C genes 
(LCE3C_LCE3B-del), a known risk factor for psoriasis. We aimed to replicate these studies in a large Dutch 
cohort.  
Methods: 1039 RA cases and 759 controls were genotyped for the LCE3C_LCE3B-del and the linked single 
nucleotide polymorphism (SNP; rs4112788). Association analysis was performed for the complete cohort 
and after stratification for the serologic markers anti-cyclic citrullinated peptide and rheumatoid factor. A 
meta-analysis was performed combining our data with the Spanish and Chinese datasets, resulting in an 
analysis including 2466 RA cases and 2438 controls. 
Results: In the Dutch cohort we did not observe a significant association of LCE3C_LCE3B-del (p=0.093) 
with RA risk. A stratified analysis for the serologic positive and negative group did not show an association 
between the genetic variants and disease risk, either. The meta-analysis, however, confirmed a significant 
association (p<0.0001, OR=1.31, 95% confidence interval 1.16-1.47). 
Conclusions: Our meta-analysis confirms the association of the LCE3 deletion with RA, suggesting that 
LCE3C_LCE3B-del is a common risk factor for (auto)immune diseases. 
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Introduction 
Rheumatoid arthritis (RA) is a chronic inflammatory joint disease affecting approximately 1% of the 
population. Although the causes of the disease are largely unknown, both genetic and environmental factors 
seem to contribute. Thus far, genome-wide association studies have revealed more than 30 risk loci 
explaining 16% of the disease variance. 
The copy number of DNA segments in the human genome varies in normal individuals and most likely this 
diversity is responsible for a significant proportion of phenotypic variation. Not much is known about the role 
of copy number variation (CNV) in the etiology of RA, but relevance of these common genetic variants is 
expected. A small number of candidate gene studies have indicated that CNVs in Chemokine ligand 3-like 1 
(CCL3L1), Fc gamma receptor 3B (FCGR3B) and pre-B lymphocyte 1 (VPREB1) are associated with RA 
disease susceptibility [77-79]. Using a genome-wide approach the Welcome Trust Case Control Consortium 
(WTCCC) reported that CNVs in the HLA region are significantly associated with the development of RA [81]. 
More recently using the WTCCC dataset, 11 rare copy number variable regions associated with RA were 
identified [82]. These regions included genes that could be directly linked to the development of RA. Another 
potential candidate CNV is the deletion of two genes of the Late Cornified Envelope gene cluster, LCE3B and 
LCE3C (LCE3C_LCE3B-del), which was recently found associated with psoriasis in several populations [175], 
as was rs4112788, a single nucleotide polymorphism (SNP)in high linkage disequilibrium with the deletion 
[176]. The observation that the risk of RA is increased in the offspring of individuals affected with other 
autoimmune disorders, including psoriasis, prompted Docampo and colleagues [177] to investigate the 
association between the LCE3C_LCE3B-del and RA in two independent Spanish cohorts. In their study an 
association was found between RA and homozygosity for the LCE3C_LCE3B-del. Recently it has been 
demonstrated that the deletion is also associated with RA susceptibility in a non-Caucasian (Chinese-Han) 
population [178]. However, they were unable to confirm the Spanish results that the association between 
LCE3C_LCE3B-del and RA risk was restricted to anti-CCP-positive patients. We sought to replicate these 
studies in a similarly powered Dutch cohort. A total of 1039 RA cases and 759 controls were genotyped for 
LCE3C_LCE3B-del, and we investigated whether these genetic variants are associated with RA. Additionally, 
we combined the Spanish, Chinese and Dutch data in a meta-analysis.  
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Materials and Methods 
 
Ethics statement 
The ethical committee of the Radboud University Nijmegen Medical Centre („„Commissie Mensgebonden 
Onderzoek (CMO) Regio Arnhem Nijmegen‟‟) approved the study (CMO number 2004/014); all patients and 
controls gave written informed consent. 
DNA samples 
All patients met the American College of Rheumatology 1987 revised criteria for RA. The patients were part of 
the Dutch Rheumatoid Arthritis Monitoring registry (www.dreamregistry.nl) (n=1039) [179, 180]. The 
controls (n=779) were participating in the Nijmegen Biomedical Study [181]. For cohort characteristics see 
Table 1. 
Genotyping 
DNA was extracted from blood using salt extraction. For the LCE3C_LCE3B-del genotyping a polymerase 
chain reaction was performed as earlier described [182]. 112 samples were genotyped in duplicate; error rate 
was 2.9% and assay failure rate was 0.3%. To validate the LCE3C-LCE3B-del genotype, we also genotyped 
the linked SNP rs4112788, which was performed using a Taqman® SNP genotyping assay (assay ID 
C__31910050_10) according to manufacturer‟s recommendations (Applied Biosystems, Nieuwerkerk aan 
den IJssel, The Netherlands). Five percent of the samples were analyzed in duplicate; all genotypes were 
concordant. The assay failure rate was 2.6%. 
Statistical analysis 
Descriptive statistics for quantitative values are given as mean ± standard deviation (SD). Both variants 
showed no deviations from Hardy-Weinberg equilibrium for either patients or controls. Co-dominant and 
recessive logistic regression models were used to assess the genetic effect of LCE3C_LCE3B-del on RA risk, 
using homozygosity for the allele without deletion as a reference category. These models were similar to 
those used in the previous studies [177, 178]. The statistical analyses were performed using SPSS software 
16.0 (SPSS Inc., Chicago, IL, U.S.A.). A meta-analysis was performed in Review Manager 5 (Review Manager 
(RevMan) Version 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008) using 
the aggregated data from this studies, Docampo et al.[177] and Lu et al. [178]. Heterogeneity of odds ratios 
(ORs) among cohorts was calculated using the Breslow-Day method, and pooled ORs were calculated under 
a fixed effects model (Mantel-Haenszel meta-analysis). A power calculation was performed using the Genetic 
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Power Calculator [183] with input values derived from Docampo et al.[177] (significance level 0.05, OR = 
1.45, allele frequency 0.62, recessive model). 
 
 
 
 
 
Table 1: Demographics of the rheumatoid arthritis cohort   
 
RA patients Controls 
Number 1043 779 
gender (female) 693 (66.4) 422 (54.2) 
age# 55.0 ± 12.7 56.3 ± 16.8 
age at disease onset## 45.3 ± 13.3 
 
RF positive### 736 (77.3) 
 
anti-CCP positive#### 286 (63.4)   
Numbers are depicted as n(%) or mean ± standard deviation. Data available for #686, ##717, 
###952, ####451 patients. RA: rheumatoid arthritis; CCP: anti-cyclic citrullinated peptide; RF: 
rheumatoid factor. 
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Results 
An overview of the demographics of the patients and controls used in this study are present in Table 1. 
Table 2 provides the results of the association analysis for theLCE3C_LCE3B-del and RA risk in the Dutch 
cohort. There were 1039 RA patients and 779 controls successfully genotyped for LCE3C_LCE3B-del. The 
LCE3C_LCE3B-del and the linked SNP rs4112788 were in near-perfect linkage disequilibrium (LD) with 
each other (r2 = 0.928 and D' = 0.984), confirming that LCE3C_LCE3B-del was genotyped accurately. 
In the Dutch cohort, we did not find evidence for an association between LCE3C_LCE3B-del and RA, at the 
genotypic (p=0.093, OR 1.18, 95% confidence interval (95%CI): 0.97-1.43 (Table 2)) nor the allelic 
level (p=0.147, OR 1.11 95%CI: 0.97-1.27 (data not shown)). It has been hypothesized that the 
LCE3C_LCE3B-del might result in a defective skin barrier repair leading to an abnormal or increased 
exposure to environmental antigens. This could lead to an earlier age of disease onset in carriers of 
LCE3C_LCE3B-del compared to non-carriers. An analysis for age of onset, however, did not show 
association with the LCE3C_LCE3B-del status (p=0.25, t-test). 
Docampo et al. [177] demonstrated that LCE3C_LCE3B-del showed the strongest association with RA in 
anti-CCP and rheumatoid factor (RF) positive patients. In the study of Lu et al. [178] no associations were 
found in the different RA subsets, these analyses were corrected for age and gender. We performed 
association analyses of the anti-CCP and RF patient subsets separately, for those patients with information 
available. We did not find an association between LCE3C_LCE3B-del and RA in any of the subsets 
analyzed (Table 2).  
We performed an overall meta-analysis, using a recessive logistic regression model unadjusted for age 
and gender, on the combined data from this study and the studies of Docampo et al.[177] and Lu et 
al.[178] (Table 3). Despite the lack of significance of the association in the Dutch cohort, in the meta-
analysis a significant association between LCE3C_LCE3B-del and RA was found (p<0.0001, OR 1.31 
95%CI: 1.16-1.47). Next to the overall analysis, we performed also a meta-analysis on the anti-CCP and 
RF subgroups combining the Spanish, Chinese and our data (Table 3), unfortunately not for all patients 
these data were available. In this subgroup analysis all previously found associations [177] between 
LCE3C_LCE3B-del and RA were significant, with the association apparently strongest in RF positive subset 
of patients (p=0.0007 OR 1.27 95%CI: 1.11-1.45) (Table 3). 
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Discussion  
Although a previously reported association of the LCE3C_LCE3B-del with RA risk did not reach 
significance in our Dutch cohort, a meta-analysis combining our data and the previously reported Spanish 
and Chinese data [177, 178] confirmed the association of the LCE3C_LCE3B-del with RA. 
Our study had a power of over 95% to find an association, although we based this calculation on the 
previously found OR of 1.45. When we recalculate the power using the OR of the meta-analysis (OR = 
1.31), the power of our study drops to 73%. A study population of 1256 samples will be needed to reach 
80% power. The ORs observed in the Dutch population are in the same direction as seen in the previous 
studies [177, 178] and our meta-analysis showed a statistically significant association of the deletion with 
RA. This suggests that a larger population is necessary to prove whether the deletion is associated with 
RA. The contradictory findings from this study and the previous RA studies [177, 178] could also be 
caused by differences in the study population, e.g. disease phenotype or ethnicity. In addition,  there is a 
discrepancy between the allele frequency of the deletion in the controls from Spain (55%) and China 
(54%) compared to The Netherlands (61%). This heterogeneity of LCE3C_LCE3B-del allele frequency in 
control groups from different ethnic backgrounds was already known from previous studies [175, 184]. 
Indeed, a recent meta-analysis confirming an association between LCE3C_LCE3B-del and psoriatic 
arthritis showed that the OR of the Spanish population was much higher than the one observed in an Italian 
population (1.66 versus 1.23) [184]. 
In our meta-analysis we used a recessive model, because this model fitted the LCE data in the psoriasis 
study best, based on the Akaike Information Criteria (AIC) [182] which is in line with the two previous 
studies on LCE3 in patients with RA [177, 178]. Although we could not identify an association between the 
deletion and RA in the Dutch cohort, addition of the data to the other studies resulted in lower P values 
than without this dataset, showing a significant contribution of the Dutch population to the overall results. 
The addition of our Dutch samples leads to a lower OR and a smaller CI than previously reported. The 
other two studies may have significantly overestimated the magnitude of the odds ratio, the so-called 
winner's curse [185]. Due to publication bias it might be possible that some studies investigating the 
same subject have not been published, this information will be important to confirm the association 
between RA and the deletion as shown in this study. 
In our subgroup analysis, we observed the strongest association in the RF positive patients. Larger 
datasets will be necessary to clarify whether the observed association is patient subset specific. In 
contrast to the results from our meta-analysis, genome-wide CNV analyses using the WTCCC RA dataset 
did not identify association with the LCE3 region [81, 82]. One study only assessed rare CNVs (population 
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frequency <5%) which excludes the LCE3C_LCE3B-del [82]. The other study included a probe covering 
the region that passed QC in their analysis (probe CNVR358.1, chr1:150,822,234-150,856,715 (UCSC 
genome browser hg18) [81]). It might be possible that the region is associated with RA in the WTCCC 
dataset at lower significance level than their genome-wide significance threshold. 
Until now, LCE3C_LCE3B-del has been associated with psoriasis, psoriatic arthritis and RA in several 
populations [175-178, 182, 184, 186, 187], whereas no association was found for atopic dermatitis 
[188]. Also in one study association with systemic lupus erythematosus was found [178], implying that 
LCE3C_LCE3B-del may be a common risk factor for (auto)immune diseases. The function of the LCE 
genes has only been studied in skin in general [189, 190] and in relation to psoriasis [191]. From these 
studies it is known that the LCE proteins are likely to be incorporated in the cornified cell envelope, which 
is an important structure in the barrier function of skin. When comparing normal and psoriasis skin, the 
genes of the LCE1, 2, 5 and 6 groups are mainly expressed in normal skin, whereas the LCE3 genes are 
predominantly expressed in psoriasis skin. Moreover, upon barrier disruption of normal skin the LCE1, 2, 
5 and 6 gene-groups are downregulated, while the expression of the LCE3 genes is upregulated. 
Altogether, these data imply a role in barrier repair for the LCE3proteins and a role in barrier maintenance 
for the other LCEs. As hypothesized by Docampo et al. [177], the absence of LCE3B and LCE3C could 
compromise barrier function of the epithelia and possibly facilitate the entrance of environmental antigens 
or pathogens. Since the LCE genes are mainly expressed in skin and oral epithelia, these would be 
relevant tissues that could facilitate the entrance of antigens or pathogens, like the Epstein-Barr virus and 
the cytomegalovirus, thereby triggering RA. We reasoned that, if this would be the case, patients with 
LCE3C_LCE3B-del might be exposed more readily to common antigens and therefore would have an 
earlier age of onset due to easy access of pathogens/triggers through the skin. However, we did not 
observe such an association between the genotype and age of RA onset . 
Our meta-analysis showed that LCE3B and LCE3C deletion is associated with RA, though the contribution 
of our large Dutch sample is small. Therefore it will be necessary to test even larger patient cohorts to 
shed more light on the possible association of the deletion in specific RA patient subsets. An interesting 
next step would be to perform functional studies to unravel the mechanism underlying this association. 
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Abstract 
Rheumatoid arthritis (RA) is a disease showing considerable heterogeneity in all its aspects, including 
response to therapy. The efficacy of disease-modifying antirheumatic drugs (DMARDs), with or without 
biological activity, has been unambiguously established. DMARDs improve the symptoms associated with 
the disease, and, even more importantly, are capable of stagnating the joint damage associated with the 
disease. Nonetheless, a considerable proportion of patients fail to achieve an adequate response and/or 
experience toxicity. This variability in treatment response between individuals has given rise to an 
extensive search for prognostic markers in order to personalize and optimize therapy in rheumatoid 
arthritis patients. Pharmacogenetics, the study of genetic variation underlying differential responses to 
drugs, is a rapidly progressing field in rheumatology that might enable personalized therapy in rheumatic 
diseases. This review will summarize the pharmacogenetics of commonly used synthetic and biological 
DMARDs. 
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INTRODUCTION 
Rheumatoid arthritis (RA) is a common, chronic inflammatory disease characterized by swelling, pain and 
stiffness of the diarthrodial joints [192]. If adequate treatment is not provided in a timely manner, RA 
results in cartilage damage, bone erosions, and joint destruction, the major causes of long-term disability. 
In addition, mortality rates in patients with RA are twice higher then rates observed in the general 
population, this being largely attributed to an increased risk of cardiovascular disease [193, 194].  
A growing body of evidence is showing that early treatment, systemic evaluation of disease activity and 
targeting treatment towards remission of RA results in greater improvement of clinical outcomes. To 
promote most favourable management of the disease the American College of Rheumatology (ACR) and 
European League Against Rheumatism (EULAR) created recommendations that are implementing early 
aggressive therapy and treat to target approach in the clinical setting [86, 100, 195]. Furthermore, 
treatment has been substantially improved by optimal use of synthetic disease modifying anti-rheumatic 
drugs (DMARDs) and the introduction of biologic agents, which has resulted in the induction and 
maintenance of clinical remission in a significant number of patients. 
An important advance in the assessment of therapy effects has been the adoption of composite, 
standardized and validated tools for measurement of clinical outcome such as the ACR response and the 
disease activity score 28 (DAS28) [105, 196]. The ACR response criteria are based on a core set of 
variables that include a tender joint count (TJC), swollen joint count (SJC), patient-reported pain scale 
and functional ability, patient and physician global assessments of disease activity, and an acute phase 
reactant. They are categorical in nature and allow assessment of disease activity change from baseline. 
DAS28 is based on an equation that incorporates a TJC, SJC, erythrocyte sedimentation rate, and patient 
assessment of general health and it provides a continuous measure of disease activity. Based on the 
DAS28, the EULAR response criteria are defined, which categorize RA patients in three groups; good, 
moderate and non-responders. Both measuring tools allow longitudinal analysis of disease activity in 
groups of patients with differential treatment response and are being widely used as outcome 
measurements in RA. They also provide some assessment of functional outcome and quality of life (e.g. 
visual analogue scale for general health) but do not directly assess joint destruction. 
There is no known cure for RA and the therapeutic management of the disease aims to alleviate symptoms 
and modify the disease process. Traditionally, RA has been treated with non-steroidal anti-inflammatory 
drugs (NSAIDs), glucocorticoids, and DMARDs. Although both NSAIDs and DMARDs improve symptoms 
of active disease, only DMARDs - and to certain degree glucocorticoids - can hinder or stagnate the 
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inflammatory and destructive processes thereby altering disease course and improving radiographic 
outcomes. This have made them a mainstay of RA therapy even today [192, 197, 198].  
DMARDs can be divided into two general categories: synthetic DMARDs, which suppress the autoimmune 
response in RA in a generalized way, and biologic DMARDs, which are engineered to target particular 
components of inflammatory cascade. Table 1 provides an overview of the DMARDs used for the treatment 
of RA. Synthetic DMARDs include: methotrexate (MTX), gold salts, cyclosporine, azathioprine, 
sulfasalazine (SSZ), hydroxychloroquine, and leflunomide (LFA). During the past decade insights into the 
pathogenesis and treatment of RA have accelerated at unprecedented pace, leading to introduction of 
targeted biological therapies such as inhibitors of tumor necrosis factor (TNF), interleukin-1 (IL-1), IL-6, 
co-stimulatory molecules, or B-cells [199, 200]. This significantly expanded the armamentarium of 
effective medication in treating inflammation as well as slowing joint damage. 
 
Despite these successful therapies remission is achieved in only 55% of the patients after a year of tight 
control treatment strategy [86]. Extensive variability in both drug efficacy and side effects is seen with 
almost any anti-rheumatic therapy (Table 1). To date, finding the most efficient therapy for the individual 
patient is still a process of trial and error. This, together with high costs of biological therapies, has driven 
the search for predictive pharmacogenetic biomarkers to optimize treatment.  
In the next sections, we will review the most significant pharmacogenetic findings concerning DMARDs in 
RA and discuss their possible clinical implementation and limitations. 
 
Table 1. Summary of disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis  
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Synthetic DMARDs 
 
Methotrexate  
 
MTX is the most widely used synthetic DMARD and a cornerstone in the treatment of RA, both on the basis 
of its efficacy as well as its long-term safety profile [98, 201]. However, only one-third of patients benefit 
from MTX therapy and, for some, treatment must be terminated because of adverse effects [130, 202]. To 
date, a growing body of evidence suggests that single nucleotide polymorphisms (SNPs) in folate, purine 
and pyrimidine gene networks may have predictive value [203, 204]. However, owing to many 
inconsistencies among published studies, none of the SNPs have been firmly established as a risk factor 
affecting the clinical activity of the drug. Table 2 presents pharmacogenetic studies in relation to MTX. 
Only the most studied variants will be highlighted in detail below. 
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Table2. Polymorphisms in candidate genes for differential response to MTX 
Gene Variant Functional effect of the variant Associated with  Reference 
Genes involved in MTX transport 
SLC19A1 80 G>A (rs1051266) MTX uptake Treatment outcome  [205-207] 
   Toxicity [208] 
   Not associated [209-214] 
ABCB1 3435 C>T (rs1045642) MTX uptake Treatment outcome   [209, 215-217] 
   Toxicity  [208, 214, 218] 
   Not associated [213] 
ABCC2 IV23+56T>C (rs4148396)  Toxicity [219] 
   Not associated  [220] 
Genes involved in intracellular MTX metabolism 
MTHFR 677C>T (rs1801133) 
Decreased reduction of 5,10-CH2-THF to 
5,10-CH3-THF 
Treatment outcome  
[210, 211, 221-
223] 
   Toxicity  [214, 223-229] 
   Not associated  
[208, 212, 213, 
220, 230-235] 
 1298A>C (rs1801131) 
Decreased reduction of 5,10-CH2-THF to 
5,10-CH3-THF 
Treatment outcome  [210, 224, 227] 
   Toxicity 
[208, 212, 213, 
220, 230-235] 
   Not associated  
[210, 213, 214, 
222, 223, 229, 233, 
235, 236] 
ATIC 347C>G (rs2372536) Decreased de novo purine synthesis Treatment outcome 
[213, 226, 237, 
238] 
   Toxicity [211, 226] 
   Not associated 
[207, 209, 212, 
239] 
MTHFD1 1958G>A (rs2236225) Indirect target of MTX Treatment outcome [210] 
   Not associated [219, 224] 
SHMT1 1420C>T (rs1979277) Decreased folate metabolism Treatment outcome [211] 
   Toxicity [226] 
   Not associated [224] 
TYMS 28bp tandem repeat Decreased conversion of CH2-THF to DHF Treatment outcome [207, 240] 
   Toxicity [208, 226] 
   Not associated [209, 211] 
AMPD1 34C>T (rs17602729) 
Decreased conversion of AMP to ADP and 
ATP 
Treatment outcome [210] 
   Not associated [219, 224] 
MTR 2756A>G (rs1805087) Methylation of homocysteine to methionine Toxicity [211, 241] 
   Not associated [208, 212] 
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MTRR 66A>G (rs1801394) 
Methylation of cofactors required for MTR 
action 
Toxicity [208, 211] 
   Not associated [210, 212, 219] 
ITPA 94C>A (rs1127354) Conversion IMP to ITP Treatment outcome [210, 237] 
   Not associated [213, 218, 224] 
ADORA2A 5 SNPs Adenosine A2a receptor Toxicity [242] 
GGH 452C>T (rs11545078) Increase the activity of the GGH promoter  Treatment outcome [243] 
   Not associated [217, 237] 
 16C>T (rs1800909) Unknown Treatment outcome [231] 
   Not associated [206, 226] 
 -401C>T (rs3758149) Increase the activity of the GGH promoter Treatment outcome [244] 
   Toxicity [211] 
   Not associated [212, 217] 
 14269 G>A (rs12681874) Unknown Treatment outcome [224] 
 -354G>T (rs719235) Unknown Toxicity [240] 
HLA-G 14bp deletion Persistence of anti-inflammatory conditions Treatment outcome [245, 246] 
   Not associated [218, 247] 
ABC, ATP-binding cassette; ADORA2A, adenosine A2a receptor; AMPD1, adenosine monophosphate deaminase 1; ADP, adenosine 
diphophate; ATP, adenosine triphosphate; ATIC, 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase; 
DHF, dihydrofolate; GGH, gamma-glutamyl hydrolase; HLA-G, major histocompatibility complex, class I, G; IMP, inosine monophophate; 
ITPA, inosine triphosphatase; ITP, inosine triphophate; MTHFD1, methylenetetrahydrofolate dehydrogenase 1; MTHFR, 
methylenetetrahydrofolate reductase; MTR, 5-methyltetrahydrofolate-homocysteine methyltransferase; MTRR, MTR reductase; MTX, 
methotrexate; SHMT1, serine hydroxymethyltransferase 1; SLC19A1, solute carrier family 19, member 1; THF, tetrahydrofolate; TYMS, 
thymidylate synthetase. 
 
MTX transport 
RFC-1, encoded by SLC19A1 gene, ABCB1 and ABCC2 are all involved in folate and MTX transport in and 
out of cells and have been studied extensively for association with MTX efficacy and toxicity [194-209]. 
However, conflicting data are reported. Several studies reported associations of AA genotype of 80G>A 
variant (rs1051266) in the SLC19A1 gene with increased MTX efficacy [194-196], while one study 
reported association of GG genotype of the same SNP with MTX toxicity in RA patients [208]. However, 
none of these findings could be replicated in subsequent studies [198-203]. A recent study by Owen et al. 
reported borderline associations (p<0.05) of six SNPs in the SLC19A1 gene region (rs11702424, 
rs2838956, rs7499, rs2274808, rs9977268 and rs7279445) with MTX treatment outcome, suggesting 
that other variants in this gene might also have an impact on response to MTX [224]. On the other hand, 
one study focusing on the ABCB1 variant 3435C>T (rs1045642) reported that the TT genotype was 
associated with less response [198], two other groups reported associations of the same genotype with 
remission in treated patients [204, 205], while Sharma et al. found heterozygous genotype to be 
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associated with poor response [206]. In addition, two studies reported association of the TT genotype with 
overall MTX toxicity [197, 207], while Plaza-Plaza et al. suggested involvement of the C allele in MTX 
toxicity [214]. It is worth noting that, despite the extensive research, most of the studies of variants in 
genes involved in MTX transport are modest in size, resulting in a reduced statistical power to detect true 
associations. Furthermore, there is a lack of consistency in the study design and outcome used for testing 
associations which  might explain the conflicting results.   
   
MTX metabolism 
MTX is a folic acid analogue that impedes purine synthesis. After entering the cell MTX is activated by a 
gamma-glutamyl hydrolase (GGH) to a polyglutamated form. The polyglutamated MTX blocks the 
dihydrofolate reductase (DHFR), inhibiting purine metabolism. It can also interfere with 
methylenetetrahydrofolate reductase (MTHFR), evoking increased homocysteine levels and toxicity [248]. 
While seven polymorphisms within MTHFR have been tested for association with MTX efficacy or toxicity 
[249, 250], two nonsynonymous SNPs (rs1801133, 677C>T; and rs1801131, 1289A>C) have been 
extensively studied. Functional studies showed that homozygosity for the T allele in the 677C>T variant of 
MTHFR is associated with a 60% reduction of enzyme activity, while compound heterozygosity for both the 
677C>T and 1298A>C variants is associated with a decrease of approximately 50-60% in MTHFR 
activity [251, 252], indicating that these genetic variants might be useful to predict MTX treatment 
outcome. 
Several studies have examined the 677C>T and 1298A>C SNPs for association with MTX efficacy and 
toxicity (Table 2) but they have provided inconsistent results across studies. Several groups have 
performed meta-analyses of the MTHFR variants. Fisher et al. included eight MTX studies, totaling over 
1,400 RA patients for the 677C>T and over 660 for the 1298A>C variant [249]. This analysis showed an 
association between the T allele of 677C>T variant and MTX toxicity using a fixed-effects model (odds 
ratio [OR] = 1.71; 95% CI: 1.3 – 2.2; p < 0.001). However, when the random effect model was applied, 
as the study showed large heterogeneity, the association was lost.  The fixed-effects model is being 
applied under an assumption of the same effect size between studies and the random-effects model under 
an assumption of varying effect size between studies. It is unclear, however, which of the models would be 
more appropriate, as frequencies of the SNP has not been fully explored among RA patients within each 
study population. Also, the random-effects model implicitly assumes a markedly conservative null 
hypothesis model and may be too stringent to detect positive associations of small and varying effect 
sizes. The MTHFR 1298A>C variant was not associated with increased toxicity (OR = 1.12; 95%CI = 0.8 
52 
– 1.6; p = 0.626). Owen et al. examined a retrospective cohort of 309 RA patients from the UK [236]. 
Nine SNPs within the MTHFR gene, including 677C>T and 1298A>C, were analyzed and none of them 
showed association with MTX efficacy or toxicity in this cohort. Subsequently, a meta-analysis was 
performed that included Owen et al. study [225]  and 17 studies selected from the published literature on 
MTHFR variants and MTX response in RA patients. The meta-analysis showed no association between 
MTHFR SNPs and MTX efficacy or toxicity. Two additional, more recent, meta-analyses found no 
association between either of these variants and MTX efficacy or toxicity [253, 254]. 
 
 
Leflunomide 
 
LFA, an immunomodulatory drug, is an effective DMARD with comparable potency to MTX in controlling 
signs and symptoms, and retarding further joint damage in patients with RA [255]. Dihydroorotate 
dehydrogenase (DHODH), a crucial enzyme in de novo pyrimidine synthesis, is the main molecular target 
of LFA [256]. Three groups investigated the effects of variants in DHODH on LFA response and toxicity. 
The frequency of remission was found to be increased in carriers of the C allele of a SNP located in the 
first exon of the DHODH gene (rs3213422; 19C>A) [257]. Variant 40A>C (rs3213422) in the same gene 
shows association with LFA toxicity, since homozygous AA patients were found to have 6.8-times greater 
risk of overall drug toxicity (p=0.005) [258] and in a recent study O'Doherty and colleagues reported 
association of six-marker DHODH haplotype with reduced response to LFA treatment [259]. In vitro studies 
showed that CYP450, CYP1A2, CYP2C19 and CYP3A4 could be affecting LFA activation [260]. However, 
the associations of polymorphisms in these genes and LFA response were inconsistent. Bohanec Grahar et 
al. reported that carriers of the CYP1A2*1F CC genotype had a 9.7–fold increase of risk for overall toxicity 
compared with the other genotype groups (p=0.002) [261], but they found no association between 
CYP2C19 genotypes and response or toxicity. On the other hand, Wiese et al. reported an association of 
CYP2C19 genotypes with LFA cessation due to toxicity but noticed no effect of CYP1A2 variants [262].  
 
 
Sulfasalazine   
 
SSZ is another DMARD with milder potency than MTX that is often used in the treatment of RA. SSZ 
impedes neutrophil function, decreases immunoglobulin levels and hampers function of T lymphocytes 
[263]. N-acetyltransferase 2 (NAT2) is an enzyme that plays an crucial role in the metabolism of SSZ. 
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Humans exhibit genetic polymorphisms in NAT2 resulting in rapid, intermediate and slow acetylator 
phenotypes. The reference NAT2*4 allele and over 65 NAT2 allelic variants in the 870-bp NAT2 coding 
region have been reported [264]. Few studies have evaluated the effect of NAT2 variants on SSZ toxicity in 
RA patients. In a study that included 144 RA patients, 16 experienced adverse effects, the most common 
being allergic reactions [265]. Analysis showed that slow acetylators experience adverse effects more 
frequently than patients who carry at least one NAT2*4 allele (OR: 7.73; 95% CI: 3.5 – 16.86; p<0.001). 
In a study on 114 patients, 39 of which experienced agranulocytosis, Wadelius and colleagues reported 
that patients with SSZ-induced agranulocytosis had significantly higher proportion of slow acetylators 
(69%) compared to patients that tolerated SSZ (45%; OR: 2.71; 95% CI: 1.2-6.15; p=0.015) [266]. 
These studies suggest that NAT2 genotypes might be an important determining factor of the risk for SSZ 
toxicity, although the replication studies are necessary to validate these findings. 
 
Hydroxychloroquine 
 
Hydroxychloroquine is an antimalarial agent that has been used to treat RA for more than 50 years. In spite 
of the availability of several new, more potent and more efficient agents for RA treatment, it has not 
become obsolete, mainly because of its cost-effectiveness and experience with its use. Despite decades 
of clinical use, the exact biological mechanism of hydroxychloroquine for treatment of autoimmune 
diseases is unclear. Previous findings indicated that mechanisms through which malaria parasites acquire 
resistance to hydroxychloroquine are associated with folate metabolism [267]. This finding encouraged 
Pawlik and colleagues to analyze a possible association of variants in MTHFR and hydroxychloroquine 
treatment outcome [268]. In a sample of 50 RA patients, univariate regression model analysis showed that 
the T allele of the 677C>T (rs1801133) variant of MTHFR is associated with 2.3-fold increase in 
remission rate following hydroxychloroquine treatment and haplotype analysis showed 677C-1298A 
haplotype to be associated with lower remission rate (OR: 0.37; 95% CI: 0.12-1.16; p=0.079).      
 
Pharmacogenetic studies of synthetic DMARDs have been primarily studies of variation within candidate 
genes involved in drug metabolism or mechanism of action. Understandably, the vast majority of data 
have been collected for MTX, the first-line DMARD in RA. However, despite having over 40 studies 
published for MTX pharmacogenetics alone, no single variant have been firmly and consistently 
established as strong risk factor that could affect clinical outcome of the drug. This could indicate that 
treatment response in RA is likely to be complex. Yet, vast majority of pharmacogenetic studies were 
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underpowered to detect true associations, and additional factors, such as environmental factors, ethnicity 
and study design, can also impede identification of genetic markers of response to synthetic DMARDs 
treatment in RA. Therefore, large randomized prospective studies are needed to replicate and validate 
these findings.  
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Biologic DMARDs 
 
Introduction of biologic DMARDs revolutionized the treatment of RA. The costs have restricted their use, 
but the degree of clinical benefit, including joint protection, good efficacy/safety ratio and patient 
compliance has shifted the use of biologic DMARDS in earlier phases of the disease. Nevertheless, only a 
proportion of patients respond well to treatment. This has led to the search to identify genetic markers that 
could identify patients' response.  
 
TNF inhibitors 
 
TNF is a crucial cytokine in the inflammatory process observed in patients with RA [269], therefore it is no 
surprise that the first approved biological agent to treat RA were TNF inhibitors. These drugs are showing 
an exceptional efficacy and ability to prevent further structural damage in patients who failed to respond to 
treatment with conventional DMARDs [130, 270, 271].  
Five anti-TNF agents are currently available for the treatment of RA, three of which are full-length 
monoclonal antibodies: infliximab, adalimumab and golimumab. Etanercept is a fusion protein consisting 
of the ligand-binding portion of the TNF receptor, linked to the Fc fragment of IgG1. Certolizumab is an 
antibody Fab fragment conjugated to polyethylene glycol (PEG).   
Although clinical research showed that patients that failed to respond to the initially administered anti-TNF 
agent may benefit from switching to a different TNF antagonist, which suggests a different mechanism of 
action for the anti-TNF drugs [272, 273]. A large study that included 856 patients who switched to a 
second TNF antagonist demonstrated that reasons for discontinuation of the treatment with the first agent 
were correlated to the reasons for stopping the second drug (inefficacy or adverse events) [161]. This fact 
indicates the potential value of investigating the same genetic variants for all anti-TNF drugs. 
Nevertheless, recent clinical research is suggesting that there are some crucial differences between anti-
TNF agents. For example, a study using patients from the Danish registry for biological therapies in 
rheumatology (DANBIO registry) reported that infliximab is associated with the lowest treatment response 
rates, adalimumab with the highest rates of response and disease remission, while etanercept is the best 
tolerated drug [140]. Etanercept (unlike the other agents) is also found to be ineffective in the treatment of 
Crohn‟s disease and it may have different rate of granulomatous infections compared with other TNF 
inhibitors [274]. Similarly, pharmacodynamic studies suggested differences in mechanism of action 
between agents, including differences in lymphotoxin neutralization, reverse signaling, formation of 
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complexes with TNF, apoptosis and immunogenic potential [275]. Infliximab, a chimeric agent, is not 
surprisingly the most immunogenic, with the prevalence of anti-infliximab antibodies varying from 14-
40% [127]. Antiadalimumab antibody levels were estimated at 28% in a 3-year follow-up study in RA 
patients [155]. Etanercept is the least immunogenic with a reported antidrug antibody incidence of 1–
18%, while data for golimumab and certolizumab are not published to date [127]. The clinical relevance of 
antidrug antibody response is not fully understood but they probably can have an influence on efficacy, 
pharmacokinetics and adverse event profiles of the drug. The development of anti-TNF antibodies has 
been shown to influence pharmacokinetics of infliximab and adalimumab, with the serum concentrations 
of both being oppositely related to the presence of the antibodies. Nevertheless, it does not necessarily 
lead to a impaired treatment outcome [155, 276].  
Many pharmacogenetic studies have attempted to link genetic polymorphisms to anti-TNF response. Most 
of these studies are candidate gene-based studies focusing on polymorphisms in genes known to be 
involved in RA pathogenesis and genes implicated in TNF signalling pathways (Table 3). Although some 
interesting findings have been reported on genetic variants that might have an effect on anti-TNF treatment 
response, many studies reported inconsistent results and the associations have seldom been validated in 
replication cohorts (Table 3).  
 
 
Table 3: Genetic variants in genes studied for their association with anti-TNF response 
Genetic variants Potential functional role anti-TNF response Reference 
TNFA 
-1031T>C (rs1799964) Possible influence on TNF production Not associated [277, 278] 
-857C>T (rs1799724) Affects transcription efficacy of TNF Associated [277, 279] 
  Not associated [280, 281] 
-308G>A (rs1800629) Influence on TNF production Associated [278, 282-287] 
  Not associated 
[277, 280, 281, 288-
294] 
-238G>A (rs361525) Possible influence on TNF production Associated [278, 295] 
  Not associated 
[266, 268, 270, 278, 
279] 
IL1B    
3954C>T (rs1143634) Possibly associated with IL1β production Not associated [278] 
IL10    
-1087G>A (rs1800896) Associated with IL10 production Associated [291, 296] 
IL10.R    
Microsatellites  Associated with IL10 secretion Associated [297] 
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The most thoroughly investigated gene is TNFA, the gene encoding for the TNF cytokine itself. Initial 
studies suggested a role of the -308G>A (rs1800629) variant in the promoter of the gene in anti-TNF 
response, and functional studies have proven influence of this variant on the magnitude of the TNF 
secretory response as well as circulating levels of the cytokine [288, 311]. However, most of the initial 
studies that reported positive association of the -308G>A variant in TNFA with response to anti-TNF 
therapy had small sample sizes, and many following studies on independent cohorts showed rather 
inconsistent results (Table 3). Lee et al. performed the first meta-analysis, which included six published 
studies representing a total of 311 RA patients. This study reported a positive association of TNFA -
308G>A with treatment outcome, claiming that the chance of optimal treatment response is, at least in 
part, influenced by this polymorphism. The frequency of the -308A allele was 22.1% in responders and 
45.1% in non-responders (OR: 0.33; 95%CI: 0.17-0.63; p = 0.0008) [312]. Comparable results were 
reported in the following meta-analysis that included three additional studies [313]. However, a 
subsequent meta-analysis by Pavy et al. including 12 previously published studies, supplemented with a 
large Dutch cohort (n = 426), could not replicate these findings and reported no association between the 
-308G>A variant in TNFA with response to TNF blocking agents [314]. Similar results were reported by 
Lee et al. in 2010 [315].  
So far, using candidate gene approaches, the most convincing evidence of association with response to 
anti-TNF therapy in RA patients has been found for a RA susceptibility gene, PTPRC. The initial association 
was reported in an analysis that included a total of 1,283 RA patients treated with etanercept, infliximab, or 
adalimumab who were gathered through an international collaborative consortium of nine groups [307]. Of 
the 31 RA-associated risk alleles investigated in the study, a SNP (rs10919563) at the PTPRC gene locus 
was found to be associated with EULAR good response versus no response (OR: 0.55; p = 0.0001 using 
a multivariate model) and comparable results were acquired using DAS28 change from baseline (p = 
0.0002). Also, somewhat stronger association was reported in autoantibody-positive patients (OR: 0.55; 
95% CI: 0.39-0.76) compared with autoantibody-negative RA patients (OR: 0.90; 95% CI: 0.41-1.99). 
This finding was replicated in a cohort of 1,115 UK patients with RA and a meta-analysis combining data 
from these two studies strengthened the evidence for association (p = 5.13 × 10-5) [308]. Despite these 
positive results there was no association of this variant and treatment outcome in two subsequent studies 
including 196 and 984 patients [309, 310]. 
 
Emerging genome-wide association studies (GWAS) on anti-TNF response have provided a number of 
additional potential candidate gene loci (Table 4). The first published GWAS study on anti-TNF 
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pharmacogenomics was performed by Liu et al. on a small cohort of RA patients (n = 89) [316]. 
Association was reported for markers in the MAFB and PON1 gene regions as well as in a region on 
chromosome 9 that contains the IFN-κ, MOBKL2B and C9orf72 loci, where IFN-κ is the most compelling 
candidate for involvement in anti-TNF treatment response. However, these results could not be replicated 
by a group from Spain (n=151), indicating that the initial study was underpowered to detect positive 
findings [317]. Krintel et al. reported associations of SNPs within a non-coding region surrounded by the 
TLR4 gene and the DBC1 gene, and a marker within the FOXP1 gene, with treatment outcome in a cohort 
of 196 Danish patients [309]. Plant et al. performed a GWAS analysis on 566 anti-TNF-treated patients 
from the Welcome Trust Case Control Consortium (WTCCC) [318]. A total of 171 markers showing the 
strongest evidence of association in the discovery cohort were further tested in two independent 
replication cohorts (n=379 and n=341) and seven SNPs were added in a combined analysis. These 7 
SNPs, when analyzed together, increased the explained variance in treatment outcome by a notable 5%. 
However, no single SNP reached a significance level of p < 0.01 in either of two replication samples. A 
similar multistage study design was used in a recent GWAS by Umićević Mirkov et al.[310], with 
discovery cohort comprising of 984 Dutch RA patients, and three independent cohorts that were used for 
replication (n=954, n=595 and n=272). Eight genetic loci showed decreased P values in overall meta-
analysis compared with the discovery cohort demonstrating suggestive evidence of association, with three 
markers (rs4411591, rs1813443 and rs1568885), showing directional consistency over all four cohorts 
studied. In the combined cohort, eight identified loci together explained 3.8% of the variance in the 
treatment response. Both Krintel et al.[309] and Umićević Mirkov et al. [299] found no evidence for 
association of loci previously identified in GWAS on anti-TNF response  including the PTPRC gene, 
suggesting that this locus does not play a crucial role in determining treatment response in these 
populations. However, the power of the later study to detect an association with the PTPRC locus at p < 
0.0005 in a sample of 882 patients was only 26%, indicating that these studies are still lacking 
appropriate size to detect positive associations [310].  
The results gathered from published GWAS suggest that there are no common alleles with large effect size 
that determine response to anti-TNF therapy, indicating that treatment response in RA is likely to be 
complex, even for targeted biologic therapy. Detection of a SNP with a strong genetic effect (OR > 3) 
requires recruitment of several hundred participants and to detect more modest effects (OR < 1.5) will 
require thousands of patients [319]. Most of the reported studies have been undersized to detect even 
large effects. There has also been a discrepancy in measures used to describe the outcome of the 
treatment, with some of the earlier studies using EULAR criteria rather than change in DAS28. These 
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findings warrant the need for large, sufficiently powered and well-described cohorts with homogenous 
outcome measurements in studying treatment outcome in heterogeneous disease such as RA.     
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Rituximab 
 
 
Another widely used biological is rituximab, a human-mouse chimeric antibody that targets CD20, a 
molecule found on the surface of mature and pre-B-cells [320]. Clinical and animal studies have 
highlighted the multiple roles of B cells in the immunopathogenesis of RA [321]. Clinical studies 
demonstrate that RA patients with suboptimal response to MTX and TNF inhibitors experience clinical 
benefit from rituximab, including a delay in radiographic progression [322, 323]. Several candidate gene 
studies have been published aiming to find an association with response to rituximab treatment. To date, 
two studies (one including 158 Italian and the other 144 Spanish RA patients) investigated the association 
of a -174G>C polymorphism (rs1800795) in the IL6 gene with response to rituximab [324, 325]. They 
consistently found that patients homozygous for the -174 CC genotype showed worse response to 
rituximab, with an OR of 2.83 (95% CI: 1.1-7.27; p=0.031) reported for the Italian cohort and an OR of 
4.03 (95% CI: 0.78-16.97; p=0.049) reported by the Spanish group. The influence of the F158V 
polymorphism in FCGR3A gene was also investigated by two groups. Kastbom et al. reported that 
heterozygous patients had a higher response rate then both 158FF and 158VV carriers (p=0.028 and 
p=0.016, respectively) [326]; another group found the V variant of F158V to be significantly associated 
with better treatment response (OR=4.6; 95% CI: 1.5-13.6; p=0.006) [327]. Fabris et al. also reported 
that a haplotype in the promoter of BlyS gene is associated with good response, with an OR for good 
versus non-responders being 14.4 (95% CI: 1.77-117.39; p=0.0028) [328]. Daien et al. investigated 13 
SNPs in nine candidate genes for their association with rituximab response in a group of 63 RA patients. 
They found two TGFβ1 gene variants (codon 10,  rs1800470; and codon 25, rs1800471) to be associated 
with clinical response. Patients with the CT genotype at codon 10 had a statistically significant better 
response to treatment compared with the TT genotype (OR: 1.6; p=0.002). Similarly, probability of 
responding to rituximab was higher in carriers of the GC genotype at codon 25 of the same gene (OR: 1.6; 
p=0.025). The combination of the two SNPs led to an even better response to rituximab. Patients 
heterozygous for the variant at codon 10 (CT) and codon 25 (GC) had a 2.6-fold increase in response to 
rituximab when compared with patients homozygous GG for codon 25 and TT for codon 10 (95% CI: 1.4-
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4.6; p=0.008) [329]. However, these results should be interpreted with caution, considering the small 
size of the discovery cohort and need of validation in larger independent cohorts. 
 
 
IL-1 antagonist (Anakira) 
IL-1 antagonists together with TNF inhibitors were the “first generation” biologicals to be approved for the 
treatment of RA. Although human recombinant IL-1 receptor antagonist has proven successful  in treating 
RA in clinical trials, the clinical potency of this agent is inferior to that of anti-TNF agents [330]. A clear 
candidate for a pharmacogenetic study is the IL1 gene cluster. Polymorphisms of the IL1 region have not 
only been related to interindividual differences in IL-1 production [331] but are also associated with 
occurrence and severity of RA [332]. Camp and colleagues reported a reduction in SJCs in RA patients 
treated with IL-1 receptor antagonist, which was associated with two variants in IL1 (rs17561 and 
rs1800587). They identified a considerable increase in the IL-1 receptor antagonist response rate in 
carriers of rare alleles of the IL1A variants (OR: 4.8; 95% CI: 1.8-12.7; p=0.0009 for rs17561and OR: 
4.32; 95% CI: 1.69 – 11.03; p = 0.0018 for rs1800587) [333].  
 
 
IL-6 receptor antagonist (Tocilizumab)       
IL-6 is a pro-inflammatory cytokine with pathologic involvement in RA and an interesting therapeutic 
target. Tocilizumab was developed as a humanized monoclonal antibody targeting the IL-6 receptor, and, 
to date, a number of publications demonstrated its efficacy in RA [334]. Wang et al. conducted a first 
genetic analysis of response to tocilizumab revealing putative associations at seven loci in their GWAS 
including 1,683 RA patients from six clinical studies [335]. A two-stage analysis was performed. In the 
discovery stage (n=706) the authors analyzed multiple efficacy outcome measures; DAS28 and its core 
components (SJC, TJC, visual analogue scale for general health and CRP).They identified 253 variants 
showing statistically significant association with one of the analyzed measures (p<10-5). Seven of these 
markers could be confirmed (p < 0.05 for the same end point) in a replication cohort (n=338) [324]. 
None of the identified loci have been previously implicated in RA susceptibility or response to any other 
therapy, in addition their biological significance for IL-6 treatment response is not obvious. However, 
when analyzing the predictive nature of these SNPs on DAS28 change in various genetic models, Wang 
and colleagues found them to be largely predictive [324]. 
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Abatacept 
Abatacept is a biologic agent that binds CD80 and CD86, thereby inhibiting CD28-B7-mediated co-
stimulation of T cells. Structurally, abatacept is a fusion protein of human CTLA-4 and Fc domain of 
human IgG1. Abatacept is effective in RA patients with inadequate response to anti-TNF agents as well as 
in patients that previously failed to respond to MTX treatment [336]. No studies have been published yet 
investigating the influence of genetic markers on response to abatacept treatment. 
 
 
 
 
Advanced pharmacogenetic analysis methods  
 
There is convergence of knowledge that response to therapy in RA patients is complex and derives from 
multiple etiologic factors, both genetic and non-genetic, with small effect sizes. Even though the 
individual effect of a risk factor can be small and its predictive value low, composite analysis of multiple 
known risk factors may yield better predictions. The genetic architecture of complex traits is also likely to 
be polygenic, with possible gene-gene and gene-environment interactions, hence the analysis of 
haplotypes and allelic combinations as composite markers may be more appropriate for pharmacogenetic 
traits then studies of single variants. Several studies combining genetic and non-genetic factors in a MTX 
response prediction model were published, trying to reconcile apparently conflicting results from previous 
pharmacogenetic studies. Wessels et al. identified a model including gender, rheumatoid factor, smoking 
status and disease activity at baseline, in combination with variants in ATIC, ITPA, AMPD1 and MTHFD1, 
predictive of MTX efficacy in DMARD naïve recent-onset RA patients [237]. The prediction model was 
transformed into a scoring system ranging from 0 to 11.5. Scores of ≤ 3.5 had a true positive response 
rate of 95%, whereas scores of ≥6 had a true negative response rate of 86%. The model categorized 60% 
of the patients correctly as either responders or non-responders and model evaluation on 38 additional 
patients supported initial results. The same model could also be used to predict non-response to MTX in 
patients with established RA and preceding DMARD failure, but it performed worse than in the initial study 
[337]. James et al. studied nine polymorphisms in seven genes of the folate pathway as predictors for 
MTX and SSZ combination treatment regimen in 98 RA patients [338]. The authors identified that carriers 
of the A allele of the rs1805087 variant in MTR gene in combination with either the A allele of the 
rs1051266 SNP in SLC19A1 gene or the 3R-del6 haplotype in TYMS gene have a 35-fold increase in 
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treatment response rate (95%CI: 6.9-176; p<0.0001). Dervieux et al. analyzed gene-gene interactions 
between 11 SNPs in the folate, purine and pyrimidine pathways using multifunctional dimensionality 
reduction (MDR) statistical modeling and the effects of these interactions on MTX response in a cohort of 
439 RA patients from the USA and The Netherlands [339]. Researchers also collected nongenetic 
characteristics such as age, gender, anti-cyclic citrullinated antibody status and red blood cell MTX 
polyglutamate concentrations and sought to define gene interactions with these factors. Three interacting 
SNPs, SLC19A1 80 G>A, ATIC 347 C>G and ITPA 94 C>A, showed association with MTX efficacy with 
an OR of 2.9 (95% CI: 1.9–4.2) [328]. However, replication in a cohort of 523 Swedish RA patients failed 
to identify the association between the three interacting SNPs and MTX efficacy. When the MDR analysis is 
performed on both the discovery and replication cohort (n=894 RA patients), with non-genetic 
determinants (anticitrullinated peptide antibody positivity status, age and gender) taken into account, the 
three interacting SNPs in SLC19A1, ATIC and ITPA were associated with MTX response with an OR of 2.3 
(95% CI: 1.4–3.4). These results suggest that more complex prediction models including combination of 
interacting SNPs with clinical predictors might be useful to determine treatment outcome in patients with 
RA.  
Besides these prediction models it is also increasingly recognized that system biology approaches 
deciphering complex genetic interactions may unravel contributions of genetic variants to a phenotypic 
trait. Studying the cumulative variation of polymorphisms in multiple genes acting in functional pathways 
may provide a complementary approach to the more common single SNP association approach in 
understanding genetic determinants of complex traits. Two studies have been published that followed a 
functional pathway approach, they examined genetic variants in MAPK (p38) signalling network [340] and 
TLR and NFκB signalling pathways [341], respectively. Coulthard and colleagues genotyped 38 SNPs 
spanning 12 candidate genes from the p38 network in a cohort of 968 RA patients treated with anti-TNF 
therapy [329]. Out of 38 SNPs, 12 SNPs in seven genes (RIPK1, MAP2K6, MAPKAPK2, RPS6KA5, 
RPS6KA4 and MKNK1) had an impact on the improvement in DAS28 at 6 months (p < 0.1), 
approximately 32% of investigated SNPs reached this level of significance, which was much greater than 
the 10% that would be expected by chance. However, Potter et al. after analysis of 187 SNPs spanning 24 
candidate genes involved in TLR and NFκB signalling pathways in 909 RA patients found only 12 SNPs 
spanning nine genes to be nominally associated with treatment response [303]. The identified variants are 
ideal candidates to be incorporated into prediction models, as described above. Needless to say, several 
genetic variants (with small effects) in a specific pathway might have a larger effect analysed together, in 
contrast to single SNP analysis. 
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Interesting results were also reported by exploratory pathway analysis performed on two GWAS of anti-TNF 
treatment response. Krintel et al. used gene-set enrichment analysis, a pathway-based approach, to search 
for biologically important pathways that are overrepresented among their GWAS hits [298]. Interestingly, 
one of the top-ranked pathways in their analysis was the TNF-receptor signaling pathway. A similar 
approach was implemented by Umićević Mirkov and colleagues [299]. Using Ingenuity Pathway Analysis 
(IPA), the authors identified eight networks (p=10-41 for the highest scoring network) involved in 
metabolic disease and biological processes underlying inflammatory response and cell morphology. The 
networks included genes implicated in TNF signalling (NFκB) and antibody formation (IgG). These results 
are suggesting that system biology approaches can aid in the selection of genes that might be implicated 
in treatment outcome for further genetic analysis.  
 
 The results of these studies are strengthening the initial hypothesis about the complex nature of treatment 
response in RA patients. With the increasing number of the pharmacogenetic studies, our knowledge 
about genetic and nongenetic factors predicting response will develop. This knowledge can be used to 
select the optimal treatment for the patient, although this will only be possible if the clinical and/or genetic 
markers can predict treatment outcome with high sensitivity and specificity. In addition, it will give us 
insight in the biological pathways involved in the treatment of RA and might give new leads for the 
development of new treatments. 
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CONCLUSION AND FUTURE PROSPECTIVES 
 
Pharmacogenetic studies offer a promising future and yet have a challenging present. Despite research 
spanning over a decade, no genetic marker have been identified that can be used for treatment 
optimization in a clinical setting. By changing the approaches for the identification of genetic factors 
associated with treatment outcome, implementation of the results in a clinical setting might be a reality 
within the next ten years.  
 
First, more attention should be paid to the “polygenic” architecture of treatment outcome. Combining a 
substantial number of common alleles with small-to-moderate effects influencing treatment response 
might result in better prediction models compared to the single SNP analysis used in most studies. 
Second, the focus should switch from common variants with small effect sizes to rare genetic variants with 
large effect sizes. Thus far these have been neglected totally as they are not adequately captured on 
genome-wide association platforms. With the introduction of next-generation sequencing these rare 
variants can be identified. Besides, these methods are already used for diagnostic testing, which will 
greatly facilitate introduction in the clinic. Third, researchers should also focus on other phenotypes than 
the commonly used outcome measures DAS28 or ACR response. Since both measures are composed of 
several parameters, it is very unlikely that they reflect a single biological entity of treatment outcome in 
RA, which is a prerequisite for successful genetic association studies. Interestingly, a recent study indeed 
showed that pain and inflammation pathways are (partly) independently targeted by anti-TNF medication 
[115]. Also, joint destruction might not correlate directly with clinical signs of inflammation as determined 
by the DAS28 and ACR instruments. Therefore, focusing on these signs in association studies might serve 
as better alternatives for currently used response criteria. Hence, analysis of less complex phenotypes 
(e.g., pain or joint destruction), potentially closer to the biological basis of RA, might aid the identification 
of genetic factors determining treatment outcome. Finally, it is crucial to collect large, well-characterized 
patient samples that are accessible to all researchers in the field, allowing standardized and reliable 
marker identification.  
 
Once identified, these genetic makers could not only help discriminating non-responders and responders 
to currently available therapies but will also provide us insight into disease pathogenic pathways and 
potential new therapeutic targets. 
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Abstract 
Background. Treatment strategies blocking tumor necrosis factor (anti-TNF) have proven very successful 
in patients with rheumatoid arthritis (RA). However, a significant subset of patients does not respond for 
unknown reasons. Currently, there are no means of identifying these patients before treatment. This study 
was aimed at identifying genetic factors predicting anti-TNF treatment outcome in patients with RA using a 
genome-wide association approach. 
Methods. We conducted a multi-stage, genome-wide association study with a primary analysis of 
2,557,253 single-nucleotide polymorphisms (SNPs) in 882 patients with RA receiving anti-TNF therapy 
included through the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry and the database of 
Apotheekzorg.  Linear regression analysis of changes in the Disease Activity Score in 28 joints after 14 
weeks of treatment was performed using an additive model. Markers with p<10-3 were selected for 
replication in 1,821 RA patients from three independent cohorts. Pathway analysis including all SNPs with 
p<10-3 was performed using Ingenuity.    
Results.  772 markers showed evidence of association with treatment outcome in the initial stage. Eight 
genetic loci showed improved P value in the overall meta-analysis compared with the first stage, three of 
which (rs1568885, rs1813443 and rs4411591) showed directional consistency over all four cohorts 
studied. Network analysis indicated strong involvement of biological processes underlying inflammatory 
response and cell morphology.  
Conclusion. Using a multi-stage strategy, we have identified eight genetic loci associated with response to 
anti-TNF treatment. Further studies are required to validate these findings in additional patient collections. 
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Introduction 
Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disease characterized by polyarthritis, joint 
damage and functional disability [342]. It cannot be cured, and treatment is directed towards reducing the 
symptoms associated with the disease. 
Tumor necrosis factor α (TNFα) is a pleiotropic, proinflammatory and immunoregulatory cytokine that 
plays a crucial role in RA [113, 343]. The introduction of TNF-blocking agents, such as infliximab, 
etanercept and adalimumab, revolutionised the treatment of RA, most notably because of the excellent 
clinical efficacy and ability of these agents to prevent further structural damage in patients who failed to 
respond to treatment with conventional disease-modifying anti rheumatic drugs (DMARDs) [137, 344]. 
Despite this success, a substantial proportion of patients with RA (~30%) treated with TNF inhibitors do 
not display any significant clinical improvement [133, 134]. Given the expensive treatment regimen and 
the potential side effects associated with the treatment, the idea of a priori prediction of response to anti-
TNF agents in patients with RA is a highly relevant topic [161, 345]. 
Studies of clinical parameters and biomarkers have identified several factors that influence anti-TNF 
treatment outcome, including concurrent use of DMARDs, lower baseline Health Assessment 
Questionnaire score, gender, smoking, serological status, TNF levels at the site of inflammation, and the 
synovial microarchitecture. However, these factors explain only a relatively small proportion of the 
observed variance in response (R2 = 17-29%) and are, therefore, not suitable to be used as predictors in 
clinical setting [161-164]. In addition, effort has been put into the identification of genetic markers 
predicting anti-TNF treatment outcome. Most of these studies are candidate-gene based studies, focusing 
on polymorphisms in genes known to be involved in RA pathogenesis and genes implicated in TNFα 
signalling pathways [160]. The most thoroughly investigated gene is TNFA, encoding TNFα, the target of 
anti-TNF treatment. Initial studies suggested a role for a variant in the promoter of the gene (-308G>A) in 
anti-TNF response, although recent meta-analyses do not support this association [314, 315]. So far, 
using the candidate gene approach, the most convincing evidence of association with response to anti-
TNF therapy in patients with RA is found for an RA risk allele at the PTPRC gene locus [307, 308].  
A number of additional potential candidate loci have been suggested based on the results of three 
genome-wide association studies (GWAS) [309, 316, 318]. In a GWAS of 566 patients with RA, Plant et 
al. [318] found evidence of association at seven genetic loci with response to TNF blockade, two of which 
mapped within genes: PDZ domain-containing protein 2 (PDZD2) and eyes absent homolog 4 (EYA4). In a 
small study (n=89) by Liu et al.[316], association was reported for markers in the MAFB and PON1 gene 
regions as well as in a region of chromosome 9 that contains the interferon kappa (IFN-κ), MOBKL2B and 
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C9orf72 loci. The most compelling candidate for involvement in anti-TNF treatment response in this study 
is IFN-κ, since type I IFNs play a definite role in inflammatory disease and autoimmunity [346]. However, 
these results could not be replicated by others [309, 317]. Krintel et al. [309] reported associations of 
single nucleotide polymorphisms (SNPs) within a non-coding region surrounded by the TLR4 gene and 
the DBC1 gene and a marker within the FOXP1 gene with treatment outcome in a cohort of 196 Danish 
patients.  
To determine whether the reported loci reflect true associations, and to search for novel loci that influence 
differential response to anti-TNF therapy, we performed a GWAS in a cohort of 882 Dutch patients with RA 
receiving anti-TNF therapy. 
 
 
Materials and methods 
Patients and study design  
A multistage GWAS was performed including 984 patients with RA receiving anti-TNF medication (stage 
1) with subsequent follow-up of the most significant signals in two replication cohorts (stage 2 (n=954) 
and 3 (n=867)).  
For the initial genome-wide association analysis, patients were recruited through a collaborative effort in 
which 669 patients were included as part of the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry 
(http://www.dreamregistry.nl) and 315 patients were enrolled through the database of ApotheekZorg, 
which facilitates the Dutch distribution of adalimumab. All patients were diagnosed with RA according to 
the 1987 revised American College of Rheumatology (ACR) criteria and were treated with anti-TNF 
according to the indications in the Netherlands: Disease Activity Score 28 (DAS28) > 3.2; previous 
failure on at least two DMARDs, one of which has to be methotrexate; biological naïve [131]. We used the 
DAS28 change at three months as outcome for our analysis. Patients who stopped treatment within the 
first three months were not included in the study. All patients gave written informed consent, and the study 
was approved by the ethical committees of the participating hospitals. 
For stage 2, data from 954 RA cases treated with anti-TNF were selected from nine different cohorts as 
part of the ACR Research and Education Foundation (REF) “Within Our Reach” project: Autoimmune 
Biomarkers Collaborative Network (ABCoN), Academic Medical Center Amsterdam (AMC), 
Behandelstrategieen voor Rheumatoide Arthritis (BeSt), Biological in Rheumatoid arthritis Genetics and 
Genomics Study Syndicate (BRAGGSS), Brigham Rheumatoid Arthritis Sequential Study (BRASS), 
Epidemiological Investigation of Rheumatoid Arthritis (EIRA), Immunex Early Rheumatoid Arthritis (ERA) 
74 
study, Karolinska Institutet (KI) study, READE, formerly Jan van Breemen Institute (READE) study, 
Treatment of Early Aggressive RA (TEAR) – this collection has been reported on previously [307, 347].  
Finally, stage 3 included two previously described cohorts: (1) Wellcome Trust Case Control Consortium 
(WTCCC) comprising 595 patients with RA from the UK [318]; (2) 272 patients with RA from France 
ascertained through ReAct [348].  
 
Genotyping and preimputation quality control (QC) 
For stage 1, genotyping was performed using the Illumina HumanHap550-Duo Bead Chip or the 
Human660W-Quad BeadChips, according to the instructions of the manufacturer (Illumina, San Diego, 
California, USA).  
Preimputation QC procedures were applied using PLINK software [349]. SNPs that had minor allele 
frequency (MAF) <0.05 and call rates <95% were excluded, as well as SNPs with extreme departures 
from Hardy-Weinberg equilibrium (p<1x10-5). Subsequently, QC filtering was performed at the sample 
level. Four samples were excluded because of gender mismatch with phenotypic data, and 21 samples 
because of a genotyping rate <95%. Cryptic relatedness between study participants was examined by 
estimating identity by descent (IBD). Seven DNA samples were excluded based on a proportion of IBD (PI-
HAT)>0.125. Lastly, principal components were computed to adjust for population stratification using the 
EIGENSTRAT package [350]; 59 individuals were removed as outliers, based on the EIGENSTRAT default 
filter. After QC, 882 individuals were left for analysis. For the replication cohorts, the same QC criteria 
were used. 
 
Imputation 
To obtain a marker set common to all studies and to increase overall coverage of the genome, imputation 
was performed using HapMap2 release 21 (downloaded from http://www.sph.umich.edu/ 
csg/abecasis/MACH/download/HapMap-r21.html). Haplotype phasing using MaCH software 
(http://www.sph.umich.edu/csg/abecasis/MACH/index.html) [351] was followed by genotype imputation 
by Minimac (http://genome.sph.umich.edu/wiki/Minimac).  
Post-imputation QC criteria were MAF ≥ 1% and good imputation quality, which was defined as RSQR ≥ 
0.3. In total, 2,557,253 SNPs were included in the analysis.  
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Stage 1 GWAS  
The additive genetic effect of each SNP allele on change in DAS28 at 3 months of treatment was estimated 
using linear regression analysis with adjustment for baseline DAS28 and the first three principal 
components derived using EIGENSTRAT. These analyses were performed using the Mach2qtl software 
package [352] (downloaded from http://www.sph.umich.edu/csg/abecasis/ MACH/download/HapMap-
r21.html). 
The Dutch samples were not genotyped in one run therefore the results were analyzed using a meta-
analysis approach that combines study-specific β estimates based on the fixed-effects model and using 
the inverse of the variance of the study-specific β estimates to weigh the contribution of each study. 
Calculations were performed in the METAL package (www.sph.umich.edu/csg/abecasis/metal). Within-
study genomic control correction was applied to the variance of β estimates using λ factors specific to 
each study (λ1 = 1.013, λ2 = 1.016, λ3 = 0.996).  
SNP selection for replication in stage 2 and 3 
Markers demonstrating association with DAS28 change (p<10-3) in stage 1 were selected for replication. 
Pruning of hits based on linkage disequilibrium (LD) was performed before replication: all SNPs with a 
HapMap Utah residents with ancestry from northern and western Europe (CEU) pair-wise correlation 
coefficient (r2) > 0.8 with the most strongly associated SNPs in a locus were eliminated. A total of 772 
independent loci were left for replication. Replication analysis in stage 2 was carried out using existing 
GWAS scan data from the REF collection. Those SNPs that passed the p < 0.05 threshold in stage 2 were 
further evaluated using GWAS data from two collections (WTCCC and ReAct) in stage 3. A meta-analysis 
using the METAL package was performed.   
  
Explorative analysis for functional relation between genes identified in stage 1 
All markers showing association with DAS28 change (p<10-3) in stage 1 were investigated for functional 
interactions by Ingenuity Pathway Analysis (IPA) software (Ingenuity Systems, www.ingenuity.com) using 
an unsupervised analysis. IPA computes a score for each network accordingly to the fit of the user‟s set of 
input genes. The score, representing the –log (P value), indicates the likelihood of focus genes (genes 
harbouring associated SNPs) in a network being found together due to a random chance.  
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Figure 1: Study design of a multi-stage genome-wide association studies (GWAS) of response to anti-
tumor necrosis factor (TNF) medication in patients with rheumatoid arthritis (RA). We started out with 
meta-analysis of GWAS data from a Dutch cohort comprising 882 patients with RA treated with anti-TNF 
medication. We selected 772 single nucleotide polymorphisms (SNPs) that reached p<0.001, which 
were further followed-up in stage 2 samples (N=954 individuals). Thirty-eight SNPs out of 768 
investigated in stage 2 passed p<0.05 and were further investigated in two separate cohorts in stage 3 
(N=595 and N=272 individuals). MAF, minor allele frequency; QC, quality control. 
 
 
 
 
 
Results 
Figure 1 presents an overview of our study approach. The baseline characteristics of the patients included 
in the study are summarized in Table 1.  
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Table 1: Study population characteristics      
  Stage 1 
 
Stage 2  
 
Stage 3  
 Combined   DREAM ApotheekZorg       REF Col* 
 
WTCCC ReAct 
Number 984 669 (69.7) 315 (30.3)  954 595 272 
Gender female (%) 68.6 67.8 70.4  75.6 77.3 77.9 
Anti-TNF agent        
   Infliximab 225 (22.9) 225 (33.7)   415 (43.5) 268 (45.0)  
   Adalimumab 638 (64.8) 323 (48.2) 315 (100)  174 (18.2) 68 (11.4) 272 (100) 
   Etanercept 121 (12.3) 121 (18.1)   365 (38.3) 259 (43.6)  
MTX co-medication (%) 73.4 69.2 82.2  65.6 85.6 50 
DAS28        
   Baseline 5.5 ± 1.2 5.3 ± 1.3 5.8 ± 1.0  5.5 ± 1.2 6.7 ± 0.9 5.9 ± 1.0 
   DeltaDAS (14 weeks) 3.6 ± 1.3 3.9 ± 1.3 3.1 ± 1.1     
*The American College of Rheumatology Research and Education Foundation (REF) collection used for Stage 2 is composed of 9 different cohorts  – 
Autoimmune Biomarkers Collaborative Network (ABCoN), Academic Medical Center Amsterdam (AMC), Behandelstrategieen voor Rheumatoide Arthritis 
(BeSt), Biological in Rheumatoid arthritis Genetics and Genomics Study Syndicate (BRAGGSS), Birgham Rheumatoid Arthritis Sequential Study 
(BRASS),Epidemiological Investigation of Rheumatoid Arthritis (EIRA), Immunex Early Rheumatoid Arthritis (ERA) study, Karolinska Institutet (KI) study, Jan 
van Breemen Institute (READE) study, Treatment of Early Aggressive RA(TEAR) 
Numbers are depicted as n(%) or mean ± SD. 
DAS, Disease Activity Score; MTX, methotrexate; TNF, tumor necrosis factor.  
 
 
Genome-wide association analysis 
In stage 1, 2,448,996 SNPs were tested for association with anti-TNF outcome in the Dutch population. Of 
these SNPs, 2,359 showed evidence of association with treatment response (P value<10-3, online 
supplementary table, available at: http://ard.bmj.com/content/suppl/2012/12/10/ annrheumdis-2012-
202405.DC1/annrheumdis-2012-202405supp_table1.pdf). LD pruning reduced the number of SNPs 
prioritized for replication analysis to 772.   
We aimed to replicate the findings in 954 patients from the REF collection for stage 2 of our study. A total 
of 768 SNPs passed the QC in the second stage replication cohort. Thirty-nine markers showed nominally 
significant (p < 0.05) association with treatment outcome under an additive model, 20 of which 
demonstrated directionally consistent association and a resulting improvement in the association signal in 
a stage 1 and 2 combined meta-analysis (online supplementary table 2, available at: 
http://ard.bmj.com/content/suppl/2012/12/10/annrheumdis-2012-202405.DC1/annrheumdis-2012-
202405supp_table2.pdf). 
In stage 3, the 39 SNP stage 2 markers were further inspected for replication in two independent GWAS, 
comprising 595 patients from the UK and 272 patients from France (ReAct), separately. One SNP 
(rs11642036) failed QC criteria in both replication cohorts, leaving 38 SNPs for analysis. None of the 
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tested SNPs showed nominal association with treatment outcome in these cohorts (Table 2). However, the 
meta-analysis including all cohorts showed improved association signals for eight SNPs compared with 
our stage 1 results, three of which, rs1568885, rs1813443 and rs4411591, demonstrate directional 
consistency over all four studied cohorts (Table 2).  
None of the SNPs previously reported to be associated with treatment outcome showed evidence for 
association in the Dutch stage 1 cohort (Table 3) [307-309, 316, 318].  
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Table 3: Initial GWAS association results for loci previously reported to be associated with anti-TNF 
treatment response  
SNP Chr MAF Gene PGC β 
SNPs from Liu et al. [316] 
rs983332 1 0.18 - 0.603 0.031 
rs928655 1 0.23 GBP6 0.051 0.109 
rs13393173 2 0.19 LASS6 0.71 -0.006 
rs437943 4 0.34 - 0.93 0.0006 
rs10945919 6 0.32 AKO93144 0.44 0.03 
rs854555 7 0.33 PON1 0.61 0.018 
rs854548 7 0.25 PON1 0.61 0.0102 
rs854547 7 0.35 PON1 0.52 0.0225 
rs868856 9 0.31 MOBKL2B 0.65 -0.0218 
rs2814707 9 0.26 MOBKL2B 0.95 -0.002 
rs3849942 9 0.26 C9orf72 0.98 -0.0069 
rs774359 9 0.27 C9orf72 0.89 -0.0159 
rs6138150 20 0.18 - 0.66 0.0329 
rs6028945 20 0.14 - 0.78 -0.0635 
rs6071980 20 0.12 - 0.74 -0.0026 
SNPs from Plant et al. [318] 
rs12081765 1 0.39 - 0.73 -0.024 
rs4694890 4 0.49 TEC 0.4 0.042 
rs1532269 5 0.43 PDZD2 0.92 0.051 
rs17301249 6 0.18 EYA4 0.36 -0.05 
rs1350948 11 0.14 - 0.38 0.0642 
rs7305646 12 0.50 - 0.39 0.05 
rs7962316 12 0.40 BC118985 0.92 -0.026 
SNPs from Krintel et al. [309] 
rs10520789 15 0.13 NR2F2 0.47 0.071 
rs11870477 17 0.13 MAP2K6 0.67 0.073 
rs16973982 15 0.14 NR2F2 0.60 0.072 
rs8046065 16 0.10 CREBBP 0.12 0.146 
rs885814 1 0.32 ALPL 0.49 0.053 
rs869179 1 0.34 ALPL 0.75 0.016 
rs2722824 9 0.30 TLR4 0.33 -0.053 
rs885813 1 0.43 ALPL 0.30 0.049 
rs1875620 9 0.46 C9orf47 0.26 0.051 
rs11525966 9 0.45 C9orf47 0.19 0.051 
PTPRC  
rs10919563 1 0.13 PTPRC 0.384 -0.079 
Chr, chromosome; MAF, minor allele frequency; PGC, p values with genomic control correction applied; SNP, single nucleotide 
polymorphism. 
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Explorative pathway analysis of stage 1 
We explored the stage 1 dataset for potential functional relationship between genes that showed evidence 
of association at p<10-3 with treatment outcome using the IPA. This resulted in the identification of eight 
networks. The highest scoring network (p=10-41) included 26 genes identified in the genome-wide 
association analysis stage 1, and nine additional interacting genes (Figure 2). Importantly, this network is 
predicted to be involved in metabolic disease and biological processes underlying inflammatory response 
and cell morphology and contains genes implicated in TNF signaling (NFκB) and antibody formation 
(IgG).  
 
Figure 2. Top gene network derived from Ingenuity Pathway Analysis. Genes/gene products are represented 
graphically as nodes, and the biological relationship between two nodes is represented as an edge (line). Grey 
colour of the node indicates genes that were identified in the stage 1genome-wide association studies (p<0.001), 
and white indicates that the molecule was added from the Ingenuity Knowledge Base. Dashed lines indicate indirect 
interactions; solid lines indicate direct interactions. The style of the arrows indicates specific molecular 
relationships (A acts on B, A binds to B), and dotted lines indicate an indirect interaction. All edges are supported 
by at least one reference from the literature or from canonical information stored in the Ingenuity Knowledge Base. 
Nodes are displayed using various shapes that represent the functional classes of the gene product (square, 
cytokines; diamond, enzyme; circle in a circle, complex/group; trapezium, transporter; ellipse lying, transcription 
regulator; ellipse standing, transmembrane receptor; dotted rectangle, ion channel; rectangle, ligand-dependent 
nuclear receptor; triangle, kinase; dotted square, growth factor; circle, other). 
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Discussion 
In this report, we described the results of the largest GWAS of response to anti-TNF treatment in patients 
with RA conducted to date.  
Using a multistage study design, we identified eight genetic loci showing suggestive evidence of 
association (improved p values) with treatment outcome in our overall meta-analysis, with three markers 
(rs4411591, rs1813443 and rs1568885) showing directional consistency over all four cohorts studied. In 
the combined cohort, eight identified loci together explain 3.8% of the variance in the treatment response. 
Although no single SNP reached a genome-wide level of significance (p<5x10-8), these variants represent 
excellent candidates for further investigation.  
Of the eight markers with suggestive evidence of association, two map to an intergenic region in which the 
nearest gene is interesting in terms of its biological function. The SNPs, rs12142623 and rs4651370, are 
located ~400 kb downstream from the phospholipase A2, group IVA (PLA2G4A) gene. The protein 
encoded by PLA2G4A is a phospholipase enzyme involved in generation of eicosanoids, molecules with 
regulative function in inflammatory responses. TNFα is one of the first known stimuli for PLA2G4A 
activation, through action of both TNF receptor subtypes [353]. It might be possible that the identified 
SNPs influence long-range regulatory elements. 
In addition, three of the eight identified SNPs map within genes. The marker rs4411591 maps to the 
Loc100130480, encoding an hypothetical protein, while rs2378945 is located in the nucleotide-binding 
protein-like (NUBPL) gene. NUBPL encodes a protein required for the assembly of the respiratory chain 
NADH dehydrogenase (complex I). Finally, rs1813443 is located in the intronic region of contactin 5 
(CNTN5), a member of the immunoglobulin superfamily, which is thought to have a role in the formation 
of axon connections in the developing nervous system [354]. Little is known about the possible 
involvement of these genes in inflammatory disease, and there are no apparent functional links to anti-TNF 
treatment outcome, yet. If association with anti-TNF response can be confirmed in additional replication 
studies, future functional studies are needed to prove the biological link with anti-TNF response.  
We did not find any evidence for association for the loci identified from previously published GWAS on 
anti-TNF response [298, 305, 307] or for the PTPRC gene (Table 3) [296, 297] in the Dutch patients 
included in our stage 1 GWAS, suggesting that these genes do not play a major role in anti-TNF treatment 
outcome in our population. Nevertheless, the power of our study to detect an association with PTPRC loci 
at p<0.0005 in a set size of 882 patients was 26%. 
However, the top network constructed with IPA indicated involvement of the genes showing suggestive 
association in stage 1 GWAS in following processes: cell morphology, metabolic disease and 
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inflammatory response. This is in line with the expected biological function of anti-TNF; TNFα is an 
important mediator of insulin resistance and it also impedes insulin-mediated glucose uptake [355]. More 
importantly, other studies showed a positive long-term effect of TNF antagonists on insulin resistance, 
which correlated with improvement in disease activity [356, 357]. The identified network also harbours 
two interesting interacting molecules: NFκB and IgG. NFκB is a transcription regulator that is preferentially 
activated by TNF and is the main downstream target of the TNF signaling pathway [358]. The finding that 
the genes identified through the GWAS interact with IgG is particularly interesting, since response failure 
and side effects of anti-TNF due to immunogenicity are not rare and it has been found that anti-infliximab 
antibodies are exclusively of IgG isotype [154]. Both molecules might have a central role in determining 
the outcome of treatment with anti-TNF agents. Besides this network, we could map the most prominent 
associations from stage 1 to the VAV1 and SPRED2 genes. VAV1 has been found to protect T cells from 
Fas-mediated apoptosis in Jurkat leukaemia T cells [359], and it has been confirmed that patients with RA 
show differential sensitivity to apoptosis of peripheral blood lymphocytes induced by anti-TNF therapy 
[360]. SPRED2 is a known RA risk loci [60]. This network might represent new leads and new additional 
candidates for future research. 
Our study, which included 2,703 patients with RA treated with anti-TNF agents, is the largest GWAS of 
treatment outcome to date. However, our sample size still remains modest compared with genetic studies 
of risk of RA [60, 61] and other complex traits [361, 362]. Also, there are important aspects that may 
affect our results. There is considerable disease heterogeneity in RA. In our dataset, there is a difference 
in, for example, the number of women included in the studies, but also type of anti-TNF treatment and co-
medication use (Table 1). Furthermore, the REF collection used for replication in stage 2 consists of nine 
smaller cohorts from several populations. Hence, combining results across four different cohorts of RA 
patients that are rather diverse in subject ascertainment and assessment and previous treatment can lead 
to different effect estimates among studies and false negative results. In addition, the DAS28 score, used 
as measure for treatment outcome in our study, is a composite score including four measures: swollen 
and tender joint counts, erythrocyte sedimentation rate, and self-reported general health. This score is a 
powerful tool for measuring treatment response in a clinical setting. However, it is likely that this complex 
measure is influenced by genetic effects that are individually modest and would require large sample sizes 
to be detected. 
In the present study, we have identified eight genetic loci that show evidence of influencing anti-TNF 
treatment response based on a multistage approach in a population of 2703 Caucasian patients with RA. 
Our findings require further validation in independent cohorts and/or at a functional level. 
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Abstract 
Background Rheumatoid arthritis (RA) patients rate pain relief as the highest priority in treatment. 
Treatment strategies blocking tumor necrosis factor (TNFi) have proven very successful in pain reduction. 
Interestingly, recent research indicates that inflammation and pain pathways are important, partly 
independent, targets of TNF blocking therapy. Therefore genetic factors predicting pain relief are important 
to personalize treatment of RA patients.  
Objective We aimed to identify genetic factors predicting pain reduction upon TNFi treatment in patients 
with RA using a genome-wide association approach. 
Methods We included 508 RA patients treated with TNFi agents from the Dutch Rheumatoid Arthritis 
Monitoring (DREAM) registry. Association analysis using the change of visual analogue scale of pain 
(VASpain) after 14 weeks of treatment initiation as outcome was performed on an imputed dataset under 
an additive genetic model with adjustment for baseline VAS pain. We also conducted a meta-analysis 
combining the results of the initial GWAS study with three additional GWASs on a total sample of 1287 
patients with RA. Gene-based analysis was performed using VEGAS. 
Results 2,557,253 SNPs and 490 patients passed quality control. No findings reached the threshold for 
genome-wide significance (P value ≤1x10-8) in the discovery cohort or meta-analysis. In a meta-analysis 
213 SNPs were suggestively associated (P<10-4) with change in VAS pain after fourteen weeks of TNFi 
treatment. The most significant SNP was rs2295739, located ~50kb upstream from theKCNK10 gene, 
which codes for a protein that belongs to the family of potassium channel proteins. The top hit identified in 
gene-based analysis was RET, which is known to be involved in neuronal processes and nociception. 
 Conclusions We have identified a number of suggestive genomic regions with P<10-5. Further studies 
are required to validate these findings in additional patient collections. Confirmed biomarkers can be used 
for individualized treatment of patients with RA. 
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Introduction 
Pain is the dominant and prevailing symptom of rheumatoid arthritis (RA), and the primary reason for 
patients to seek rheumatologic care [94, 95]. It is, thus, not surprising that the majority of patients with RA 
(68-88%) report pain relief as one of their highest priorities in the management of their disease [83, 84]. 
Traditionally, pain related to RA has been viewed as inflammatory pain, consequently the major treatment 
goal is suppression of synovitis [363]. However, in a large proportion of the patients with RA pain persists, 
even when the inflammation has been adequately controlled [97]. Furthermore, patients with RA complain 
of pain and tenderness not only in the affected joints but also in surrounding, apparently non-inflamed, 
tissues [364]. These findings are indicative of a non-inflammatory pain component, and a role of central 
nervous system (CNS) mechanisms for pain perception in RA. 
The pharmacologic treatment of RA has been substantially improved in the past decades by the 
introduction of cytokine blocking agents [365]. Neutralization of tumor necrosis factor (TNF), has proven 
to be a particularly successful therapeutic strategy [342]. It is widely believed that the therapeutic effects 
of TNF blockade are a consequence of rapid neutralization of inflammatory cascade in the affected joints 
[119]. Interestingly, the improvement of pain is notable rapidly after administration of TNF blocking 
agents, and well before anti-inflammatory effects of the treatment can be observed [137]. It has long been 
suspected that a direct effect of TNF inhibition on the CNS might play a role in this process. A recent study 
by Hess and colleagues showed that, following the infusion of TNF inhibitors (TNFi), functional changes in 
CNS structures which are typically involved in pain perception indeed precede the improvement of 
inflammatory signs in patients with RA [115]. This suggests that inflammation and pain pathways are 
partially independent targets of TNFi therapy. 
TNFi are effective in only a proportion (60-70%) of  treated patients with RA; this, coupled with high costs, 
adverse events and possible unintentional concomitant immune suppression associated with TNFi use, 
has fuelled the extensive search for genetic markers predicting the outcome of the therapy [133, 134]. The 
vast majority of pharmacogenetic studies of response to TNFi utilized the clinical outcome measures, 
disease activity score 28 (DAS28) or American College of Rheumatology (ACR) response criteria [174]. 
Both tools are composite scores including several disease measures of RA activity, reflecting both 
inflammatory parameters and patients‟ subjective well-being assessments [94, 185]. While this 
constellation of disease measurements is useful for clinical practice, it might be less heritable as 
compared to individual, potentially more homogeneous, disease measures, and therefore probably 
suboptimal for genetic studies.  
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The idea of using less heterogeneous traits, so called endophenotypes, as a more direct expression of 
gene effects has proven helpful in analysis of other complex traits, such as cardiovascular diseases and 
asthma [366, 367], and it has been advocated by many in the field of psychiatry [368]. These findings 
suggest that usage of less complex phenotypes, such as pain (heritability 28-71%) [369-371], might 
significantly aid the identification of genetic markers predicting differential response to TNFi agents, but 
also help elucidate the biological mechanisms behind the drug action.  
We aimed to identify and replicate genetic factors predicting pain reduction upon TNFi treatment in 
patients with RA using a genome-wide association approach. 
 
 
 
Materials and Methods 
For this study a discovery genome-wide association study (GWAS) including 490 RA patients receiving 
TNFi was performed followed by a meta-analysis in a total of 1287 TNF treated RA cases of European 
ancestry. 
Samples and clinical data 
The initial genome-wide association analysis included 508 patients assembled through the Dutch 
Rheumatoid Arthritis Monitoring (DREAM) registry (http://www.dreamregistry.nl). All patients were 
diagnosed with RA according to the 1987 revisited ACR criteria and received the TNFi therapy according 
to the regulations in the Netherlands: Disease Activity Score 28 (DAS28) > 3.2; previous failure on at 
least two DMARDs, one of which is methotrexate; no previous biological drug treatment. 
In the next step a meta-analysis was conducted combining the results of the initial GWAS study with three 
additional GWASs including: 219 TNFi treated Danish RA patients from the DANBIO study [372]; 247 RA 
cases treated with TNFi from France, assembled through ReAct [348]; and 331 patients with diagnosed RA 
from Sweden from the EIRA study [373]. All participants provided written informed consent. Each 
contributing study was approved by the relevant local institutional ethics committee. 
Clinical assessments of pain on the visual analogue scale (VAS) at the start of treatment (baseline) and 
after 14 weeks of the treatment were used in the present study. Change in VAS pain score after 14 weeks 
of treatment was used as outcome measure. 
Quality control (QC) and genotype imputation 
A whole-genome genotype imputation of single nucleotide polymorphisms (SNPs) using HapMap2 
release 21 (downloaded from http://www.sph.umich.edu/csg/abecasis/MACH/download/HapMap-
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r21.html) was applied to increase overall coverage of the genome and obtain a marker set common to all 
studies. Pre-imputation QC procedures were performed using PLINK software [349]; excluding SNPs that 
had minor allele frequency (MAF) < 0.05, call rate less than 95% or if its distribution departed 
significantly from Hardy-Weinberg expectations (HWE, P<1x10-6). Individuals with gender discrepancies 
and genotyping rate < 95% were removed, as well as those that stopped therapy before the 14th week of 
treatment. Cryptic relatedness between study participants was examined by estimating identity by descent 
(IBD), individuals with an IBD (PIHAT) >0.125 were removed. Finally, in the pre-imputation QC process 
principal components were computed to adjust for population stratification using EIGENSTRAT package 
[350], and individuals were removed as outliers based on the EIGENSTRAT default filter.  
 
After applying pre-imputation QC, imputation procedure was performed with haplotype phasing step 
performed using MaCH software (http://www.sph.umich.edu/csg/abecasis/MACH/index.html) [351], and 
followed by genotype imputation using Minimac (http://genome.sph.umich.edu/wiki/Minimac). The 
imputed data underwent an extra quality control step in which SNPs with an imputation score (RSQR) 
<0.3 and MAF<0.01 were excluded.  
 
Statistical analyses 
The additive genetic effect of each SNP allele on change in VAS pain at 14 weeks of treatment was 
estimated using linear regression analysis with adjustment for baseline VAS pain and the first three 
principal components derived from EIGENSTRAT. The linear regressions were performed using Mach2qtl 
software package (downloaded from http://www.sph.umich.edu/csg/abecasis/MACH /download/HapMap-
r21.html) [352].  
 
Results from the four separate GWASs were meta-analysed combining study-specific β estimates with the 
fixed-effects model, using the inverse of the variance of the study-specific β estimates to weight the 
contribution of each study. Meta-analysis was carried out using METAL 
(http://www.sph.umich.edu/csg/abecasis/metal) [374]. Within-study genomic control correction was 
applied to the variance of  β-estimates using λ factors specific for each study. 
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Gene-based test 
The meta-analysis results from the combined-stage GWAS were used as input for VEGAS, to convert the 
individual SNPs associations into gene-wide p values [375]. VEGAS assigns SNPs to each of 17,755 
autosomal genes according to positions on the UCSC Genome Browser (hg18 assembly). For the capture 
of regulatory regions and SNPs in LD, gene boundaries are defined as 50 kb beyond the 5′ and 3′ UTRs of 
each gene. The program also takes LD patterns between markers within a gene into account by using 
Monte-Carlo simulations from the multivariate normal distribution on the basis of the LD structure of a set 
of reference individuals (the HapMap2 CEU population). 
 
 
 
 
Results 
 
Patient populations 
Sample sizes, phenotypes and clinical variables for the four collections that are analyzed as part of this 
study are presented in the Table 1.To identify possible confounders we examined if clinical variables were 
associated with our phenotype of interest. Only baseline VAS pain was found to be strongly associated 
with the ΔVAS pain, and was accordingly used as a clinical covariate. Quantile-quantile (QQ) plots show 
no evidence of systemic inflation of association test results (Figure 1).  
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Figure 1: Quantile-Quantile (Q-Q) plots for the GWASs. Q-Q plots for the GWAS of change in VAS pain 
after fourteen weeks of TNFi treatment in (A) DREAM cohort, (B) DANBIO cohort, (C) ReAct cohort, (D) 
EIRA cohort, (E) meta-analysis. 
 
 
 
 
 
 
 Initial GWAS in Dutch cohort 
2,557,253 SNPs and 490 patients passed quality control. No genome-wide significant signals were 
observed for the Dutch discovery cohort. However, two hundred and sixty-nine SNPs were suggestively 
associated with ΔVAS pain (P<10-4). 
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Table 1: Samples and clinical data  
Collection DREAM DANBIO ReAct EIRA Total 
Sample sizes 508 219 247 331 1287 
Anti-TNF agent      
   Infliximab 101 (19.8%) 152 (69.3%) 0 149 (45.0%) 398 (30.93%) 
   Etanercept 132 (25.9%) 14 (6.5%) 0 130 (39.3%) 271 (21.06%) 
   Adalimumab 275 (54.3%) 53 (24.2%) 247 52 (15.7%) 618 (48.02%) 
Gender female (%) 67.8 79.5* 76.5* 74.6*  
MTX co-medication (%) 76.5 84.1* 50** 75.6  
Baseline VASpain 60.42 ± 23.04 53.41± 23.38** 63.73 ±20.62 56.10 ± 22.95**  
ΔVASpain (14 weeks) 20.60 ± 27.86 20.16 ± 27.95 31.26 ±28.45** 24.37 ± 28.22  
Numbers are depicted as n(%) or mean ± SD. 
TNF, tumor necrosis factor; MTX, methotrexate; VASpain, pain measured on the visual analogue scale. *,** Means are significantly 
different in comparison to DREAM at 0.05 and 0.01, respectively.  
 
 
Table 2 lists the top independent findings from the initial GWAS (P < 10-5) (SNPs in high LD, r2>0.8 with 
regional top hits were pruned out), along with the annotation information for these SNPs. Annotation of the 
SNPs with a P value <10-5 showed that identified genes are all involved in physiological processes that 
can be linked to pain processing in the brain, rs2615233 is located in the intronic region of TCF12; 
rs12417221, in function of the genes is relevant, none of these findings could be consistently replicated 
in the three other cohorts (Table 2). 
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GWAS meta-analysis results 
In a meta-analysis of the four independent cohorts 213 SNPs were suggestively associated (P < 10-4) 
with change in VAS pain after fourteen weeks of TNFi treatment. Manhattan plot of meta-analysis is shown 
in Figure 2. The most significant SNP was rs2295739 (P=2.21x10-6; MAF=0.098; β=-9.07; 
SEβ=1.92), located ~50kb upstream from theKCNK10 gene, which codes a protein that belongs to the 
family of potassium channel proteins. 
 
 
Gene based association analysis 
To provide a potential in-depth gene-wide evidence for genes associated with pain change after a TNFi 
treatment in RA patients, a gene-based analysis in VEGAS was undertaken. This revealed a number of 
additional associated genes none of which withstanding strict correction for the 17,206 genes interrogated 
(PGene=2.9x10
-6). However, the top hit identified was RET gene (PGene=2.04x10
-4), involved in neuronal 
processes and nociception. Table 3 lists the top findings from the gene-based analysis (p<0.001).   
 
 
Figure 2: Manhattan plot of GWAS meta-analysis for pain change after three months of TNFi treatment. 
Observed P values for each association test are plotted on the -log10 scale (y-axis) against SNP's 
chromosomal position (x-axis). The horizontal red line (at 5x10-8) indicates genome-wide significance
KCNK10 
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Table 3: Top findings from the VEGAS gene-based analysis  
Gene Chr #SNPs Gene-based P value Best scoring SNP Best scoring SNP P value 
RET 10 140 2.04x10-4 rs2435344 3.15x10-5 
IFNAR2 21 158 2.64x10-4 rs2248420 2.05x10-4 
CSGALNACT2 10 107 3.17x10-4 rs2435344 3.15x10-5 
C3orf63 3 108 4.95x10-4 rs957849 9.76x10-6 
TEKT 2 26 6.49x10-4 rs11164111 1.62x10-4 
MUC15 11 208 7.12x10-4 rs7115642 6.16x10-5 
C12orf53 12 35 8.11x10-4 rs11064338 5.94x10-4 
FAM129A 1 130 8.54x10-4 rs555206 8.82x10-4 
Chr, chromosome; #SNPs, number of SNPs in the gene. 
 
 
Discussion 
We performed the first and the largest genetic study of pain reduction as an alternative outcome for TNFi 
therapy in 1287 comprehensively phenotyped subjects with RA. Although none of the observed top loci in 
our GWAS met the strict criteria for genome-wide significance (p<5x10-8), we identified a number of 
suggestive genomic regions with P<10-5 that, based on their function, are highly relevant for follow-up 
studies in independent samples.  
The top-associated SNPs identified in the initial GWAS in Dutch collection could be linked to relevant 
genes (See Table 2). For instance, the TCF12 gene, which is involved in neuronal differentiation and 
plasticity [376-378]. Neuroplasticity in both peripheral and central nervous system, following 
inflammation or tissue injury, affects pain perception and development of chronic pain syndromes [379]. 
Another identified candidate is OPCML gene, which encodes the opioid-binding protein that is localized in 
the plasma membrane and may serve an accessory role in opioid receptor function [380]. While human 
opioid receptors mediate the analgesic effect of endogenous and exogenous opioids, this gene represents 
an obvious candidate for involvement in differential pain perception in the patients. Lastly, ATXN1 gene, 
which is the only known gene involved in the pathology of spinocerebellar ataxia type 1, a 
neurodegenerative disorder characterized by progressive degeneration of cerebellum, a brain structure that 
appears to play a modulatory role with regard to pain [381, 382]. Intriguingly, rs2237204 located in 
ATXN1 gene, showed a same trend and directionality (P=0.024) in DANBIO collection; however, it could 
not be replicated in French and Swedish sample.  
The results of the GWAS meta-analysis are also pointing to genes involved in brain related biological 
functions. The top hit, rs2295739, is located nearby the KCNK10 gene, which codes for protein that 
belongs to the TREK subfamily of K2P potassium channels. Although ubiquitously expressed, TREK 
subfamily proteins expression is particularly high in the embryonic and immature brain. Furthermore, it 
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remains high in adult central and peripheral nervous system, where they were believed to be important for 
sensory perception [383-387]. Recent studies confirmed that TREK channels indeed play a key role in 
neuroprotection, anesthesia, pain and depression [383, 384, 388-391]. In addition, the RET gene 
identified as a top hit in the gene-wide analysis, encodes a common glial-derived neurotropic factor 
(GDNF) family ligand receptor tyrosine kinase, expressed on the surface of non-peptidergic nociceptors. 
Signalling via the Ret tyrosine kinase receptor within the innervation targets in the dorsal root ganglion is 
one of the mechanisms that shape the development of sensory neurons [392, 393]. Ret is a critical 
regulator of several ion channels and receptors participating in the detection and transduction of sensory 
stimuli, besides Ret-deficient mice are showing elevated pain responses [394].  
The top loci identified in different stages of our analysis contain genes that are a priori strong biological 
candidates for involvement in pain sensitivity. This is in sharp contrast to results obtained in GWAS of 
change in DAS28, in which the top results indicated the overrepresentation of genes involved in the 
inflammatory processes [310]. These findings provide encouraging evidence that using the less 
heterogeneous phenotypes in pharmacogenetic studies can indeed facilitate the identification of genetic 
markers underlying differential response to TNFi therapy, but also help to better understand the different 
pathways involved in the drug action.  
A limitation of our study is the small sample size and a lack of independent replication sample for the 
meta-analysis results. Also, in our dataset there is a considerable heterogeneity between the different 
cohorts we included. The marked differences in number of women included in the studies, TNFi treatment 
and MTX co-medication are seen, as well as the differences in baseline VAS pain and change in VAS pain 
after fourteen weeks of the treatment (Table 1). On the other hand, using the change in VAS pain as 
outcome of the TNFi treatment is the obvious strength of our analysis as VAS pain is assessed in the same 
fashion in all cohorts, and is more homogeneous measure of treatment response as compared to DAS28, 
the usual outcome used for GWAS.       
For all reported putative associations replication attempts and meta-analyses across multiple independent 
samples will be essential to determine the identity of bona fide markers of change in overall pain as a 
response to TNFi therapy in patients with RA.  
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Abstract 
Background Pharmacogenetic studies of tumour necrosis factor inhibitors (TNFi) response in patients with 
RA have largely relied on the changes in complex disease scores, such as DAS28, as a measure treatment 
response. It is expected that genetic architecture of such a complex score is heterogeneous and not very 
suitable for pharmacogenetic studies. Therefore we aimed to select the most optimal phenotype for TNFi 
response using heritability estimates. 
Methods Using two linear mixed modelling approaches, we estimated heritability, together with genomic 
and environmental correlations, of TNFi drug-response phenotype ΔDAS28 and its separate components 
(ΔSJC, ΔTJC, ΔESR and ΔVAS-GH), using genome-wide single nucleotide polymorphism (SNP) data 
from 878 TNFi treated Dutch patients with RA. Furthermore, multivariate approach was implemented, 
analyzing separate DAS28 components together to investigate if this approach yields better results as 
compared to the univariate analysis of ΔDAS28 and changes in its separate components.  
Results The highest heritability estimates were calculated for ΔSJC (hgbayz
2=0.76 and hgGCTA
2=0.87) and  
ΔTJC (hgbayz
2=0.62 and hgGCTA
2=0.82); lower heritability is estimated for ΔDAS28 (hgbayz
2=0.59 and 
hgGCTA
2=0.71); while estimates for ΔESR and ΔVASGH were near or equal to zero. The highest genomic 
correlations were calculated for ΔSJC and ΔTJC (0.49), and the highest environmental correlation was 
seen between ΔTJC and ΔVASGH (0.62). Multivariate approach, canonical correlation analysis (CCA), did 
not generate excess of low P values as compared to an univariate analysis of change in DAS28.  
Conclusions Our results indicate that multiple SNPs together explain a sizable portion of the heritability of 
change in joint counts in TNFi treated patients with RA, making the joint counts the most suitable outcome 
for the study of TNFi pharmacogenetics in RA. Further studies are required to validate these findings.  
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Introduction 
Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease, with peripheral synovitis as its main 
clinical manifestation [192]. The presentation of the disease, its course and outcome are highly variable, 
with symptoms including both joint limited complaints, such as stiffness, swelling, pain and functional 
impairment, and more general complaints such as loss of general health and fatigue. This variety in 
disease expression led to the development of a disease activity scores, which take both joint and general 
complaints into account to provide a comprehensive view of disease activity [395]. Disease activity scores 
are not exclusively used to measure disease activity as such, and their development is largely the result of 
a need to appropriately monitor the effects of emerging RA treatments in clinical trials and to govern goal-
directed therapy [396, 397].  
The Disease Activity Score 28 (DAS28) is one of the two major scoring systems for evaluating disease 
activity in RA, which is widely used in both clinical trials and clinical practice [104, 105, 398]. The 
DAS28 formula incorporates information from four individually weighted components: swollen joint count 
(SJC), tender joint count (TJC), a self-determined assessment of patients‟ general health on a visual 
analogue scale (VAS-GH) and acute phase response. The original DAS28 was based on the erythrocyte 
sedimentation rate (ESR) as a measure of acute phase response, but alternative formula incorporating C-
reactive protein has also been developed and validated [399].  
The use of the disease activity scores in clinical practice is also strongly encouraged by governments and 
insurance companies in order to regulate prescription of expensive biological agents, particularly tumor 
necrosis factor inhibitors (TNFi). TNFi therapies have improved the outcome for many patients with RA, 
with marked clinical and radiographic benefits [136, 400]. Unfortunately, these medications are not 
effective in all RA patients, with up to one-third of the patients failing to display significant clinical 
improvement [133, 134]. Currently, the mechanism of non-response to TNFi  is unclear, and there 
remains a pressing need for reliable biomarkers to achieve optimal therapeutic response at earlier stages 
of RA.  
Despite extensive research pharmacogenetics of response to TNFi therapy in RA is still in an early stage, 
with no single variant reaching an unambiguous level of statistical significance [174]. Five genome-wide 
association studies (GWASs) have been performed, with the largest study including 2,706 samples, but all 
reported only loci with suggestive evidence of association [309, 310, 316, 318, 401]. All five GWASs 
used the change in DAS28 as measure for  therapy response. Although the DAS28 score is very powerful 
to measure treatment response in clinical setting, it is unclear if the  composite measurement, reflecting 
both the patients' subjective assessments of well being, biological markers of inflammation and joint 
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counts, as the most characteristic feature of the disease, is suitable for pharmacogenetic association 
analysis. No studies have been conducted to show that DAS28 is under genetic control, and there is a 
possibility that heritability of the activity score is limited. Even if this is not the case, the genetic effects 
influencing this complex assemblage of disease measurements are likely to be individually modest. 
Separate components of DAS28, on the other hand, are probably closer to the biological mechanisms 
underlying treatment response, and therefore less heterogeneous and potentially more heritable.  
Valid phenotype definition is a prerequisite for a successful genetic study, and utilization of DAS28 as 
suboptimal outcome in previous pharmacogenetic studies of TNFi response is a possible explanation for 
“negative” results of previously published GWASs. Given the limitation, we sought to refine the outcome 
paradigm by studying separate components of DAS28 individually. As this approach can ignore extra 
information provided by the cross-trait covariance, we also implemented multivariate approach, analyzing 
separate DAS28 components together. In this report, we provide heritability estimates of different 
measures of TNFi treatment outcome in patients with RA and characterize the most optimal outcome 
measures for future pharmacogenetic studies. 
 
Materials and Methods 
Samples and GWAS data 
DNA samples of 984 Dutch RA patients were collected through a collaborative effort in which 669 patients 
were recruited as a part of the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry 
(http://www.dreamregistry.nl) and 315 RA patients were included through ApotheekZorg database, which 
mediated the distribution of adalimumab in the Netherlands. All patients were diagnosed with RA 
according to the 1987 revisited American College of Rheumatology (ACR) criteria and treated with TNFi 
medication in accordance to the indications in the Netherlands [131]. Data were collected at baseline and 
after 14 weeks of the treatment, the following measures are  included in this study: 28-joint counts for 
swelling and tenderness (SJC, TJC); Westergren erythrocyte sedimentation rate (ESR) and patients self-
assessment of general health on 100mm visual analogue scale (VASGH; 0=best possible, 100=worst 
possible). DAS28 values were also calculated for these time points. Patients that discontinued treatment 
within 14 weeks after treatment initiation were excluded from the study. Written informed consent was 
obtained from all patients, and this study was approved by the institutional ethics committee of each 
participating hospital.    
Genotypes were obtained using the Illumina HumanHap 550-Duo BeadChip or the Illumina Human 660W-
Quad arrays. QC procedures were applied using PLINK software [349]. We selected biallelic autosomal 
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markers based on the following criteria: call rate >0.01, minor allele frequency >0.01 and Hardy-
Weinberg equilibrium (p<10-6). This resulted in 488,254 markers eligible for analysis. Furthermore, 
subjects with gender mismatch with phenotypic data, call rate <99% and cryptic relatedness (PI-
HAT>0.125) were excluded. Finally, principal components were computed to adjust for population 
stratification using the EIGENSTRAT package [350], and individuals were removed as outliers based on the 
EIGENSTRAT default filter. This resulted in 878 individuals available for analysis. 
In all reported analyses standardized residuals derived from simple linear regression with change in 
DAS28, or its separate components: SJC, TJC, VAS-GH and ESR, after three months of treatment were 
used as a dependent variables and baseline values of each outcome respectively as independent 
variables.  
Genomic heritability and correlation estimation using Bayesian mixed model 
In this analysis, estimation of genetic parameters was based on phenotype and SNP data. The variance 
components were estimated with a Bayesian mixed model with a random regression version of a SNP-
BLUP model using the software Bayz [402, 403]. In matrix notation, the general mixed model can be 
described as: y=μ+Zu+e, where y are the phenotypes, μ is a mean, u is a vector with SNP effects taken 
as regression coefficients for allele substitution for each SNP in the study, and Z is a covariate matrix for 
the random effects (SNP markers) containing centred SNP covariates. Residuals are denoted e. Residuals 
are here also referred to as „environment‟ from the common quantitative genetic paradigm to split a 
phenotype in genetic and environmental factors. For the distribution of e and u, the variance is estimated 
from the data, allowing to assess the relative importance of environment (e) and SNPs (u) for the analysed 
phenotypes. The approach for estimating parameters in Bayz is based on a Markov chain Monte Carlo, and 
a total of 100,000 iterations were applied. A univariate Bayesian mixed model was applied to estimate the 
heritability of each individual separate DAS28 component and DAS28, itself; and bivariate Bayesian mixed 
models were run estimating environmental and genomic covariances using a hierarchical latent variable 
model, as in [402]. Both estimates were retrieved from post-analyses made with the tool gbayz, 
implemented in the Bayz software. Heritability was calculated as: h2=σ2a/ (σ
2
a+σ
2
e), where σ
2
a is the 
additive genomic variance and σ2e is the residual variance. The genomic and environmental correlations 
were calculated as: r=Cov(A1, A2)/√VA1* VA2, where Cov(A1, A2) is the covariance between trait 1 (A1) and 
trait 2 (A2), and VA1 and VA2 are the variances of trait 1 and trait 2, respectively. Genomic variance and 
covariances are based on evaluating SNP-explained variance and covariance in each Gibbs cycle and 
averaged after all cycles had finished. From this analysis it can be assessed whether a correlation between 
traits is more of environmental or genomic origin. 
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Genomic heritability estimation using GCTA 
Software developed by Yang et al. (GCTA) was also applied for univariate model of SNP-explained 
variances as a validation of Bayesian model [404]. Briefly, this method uses the estimates of genetic 
relationship from genome-wide SNP information and incorporates these into a regression model to 
provide an estimate of the genetic variance of a given phenotype. Since this method can be highly 
sensitive to uneven linkage disequilibrium (LD) between SNPs, we calculated a modified kinship matrix in 
which SNPs are weighted according to local LD using LDAK software (http://dougspeed.com/download/) 
[405]. All further analyses of genomic heritability in GCTA were adjusted for the first three principal 
components.  
Univariate and multivariate GWAS 
The additive genetic effect of each SNP allele on change in DAS28 and each of the DAS28 components 
(SJC, TJC, VASGH and ESR) after 14 weeks of TNFi treatment was estimated using linear regression 
analysis with adjustment for first three principal components. These analyses were performed using PLINK 
software [349]. Multivariate test of association (MQFAM) (downloaded from 
http://genepi.qimr.edu.au/staff/manuelF/multivariate/main.html), implemented in PLINK, was also applied. 
The components that constitute DAS28: SJC, TJC, VASGH and ESR, were taken jointly in canonical 
correlation analysis (CCA), which extracts the linear combination of traits that explain the largest 
proportion of the covariation between the marker and all traits [406]. The results of the GWASs were 
compared by visual inspection of Quantile-Quantile (Q-Q) plots. To quantify the inflation seen in GWAS for 
ΔSJC we used permutation analysis based on 1,000 replicates to test whether the number of SNPs with P 
value below 0.0001 was significantly different from the null expectation. 
  
  
108 
Results 
Table 1 shows an overview of the demographics and outcomes for the patient population studied.  
 
Table 1: Study population characteristics  
Number 878 
Gender female (%) 68.6 
TNFi drug 
 
  Infliximab 246 (22.9) 
  Adalimumab 675 (62.7) 
  Etanercept 132 (12.3) 
MTX co-medication (%) 73.4 
DAS28 
 
  Baseline 5.5 ± 1.2 
  Δ DAS28, 14 weeks 3.6 ± 1.3 
SJC 
 
  Baseline 10.17 ± 5.49 
  Δ SJC, 14 weeks 5.52 ± 5.44 
TJC 
 
  Baseline 10.04 ± 7.40 
  Δ TJC, 14 weeks 6.37 ± 7.11 
ESR (mm/h) 
 
  Baseline 28.32 ± 22.05 
  Δ ESR, 14 weeks 10.25 ± 16.60 
VASGH 
 
  Baseline 62.54 ± 22.03 
  Δ VASGH, 14 weeks 28.61 ± 27.90 
Numbers are depicted as n(%) or mean ± standard deviation. 
 
 
 
Heritability 
SNP-based estimates of the heritability and posterior standard deviations from Bayz approach as well as 
heritability estimates and standard deviations generated with GCTA are presented in the Table 2. Although 
there are differences in the estimates generated by two approaches, they show similar trends. The highest 
heritability was estimated for ΔSJC (hgbayz
2=0.76 and hgGCTA
2=0.87), indicating that most of the variation 
seen in this trait can be attributed to common SNPs. Similarly, the heritability for ΔTJC is also estimated 
to be high (hgbayz
2=0.62 and hgGCTA
2=0.82). Somewhat lower heritability is estimated for ΔDAS28 
(hgbayz
2=0.59 and hgGCTA
2=0.71). Heritability estimates for ΔESR and ΔVASGH generated with GCTA are 
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equal to zero, while Bayesian approach provided low to moderate heritability estimates (hgbayz
2=0.18 and 
hgbayz
2=0.29, respectively). In the last two estimates, the Highest Posterior Density (HPD), a Bayesian 
confidence interval, included zero.    
 
Table 2: Heritability estimates  
 
Bayz 
 
GCTA 
 
hG
2 HPDint  hG
2 SE 
ΔSJC 0.76 0.44-0.97  0.87 0.07 
ΔTJC 0.62 0.17-0.96  0.82 0.12 
ΔESR 0.18 0.00-0.44  0.00 0.33 
ΔVASGH 0.29 0.00-0.66  0.00 0.38 
ΔDAS28 0.59 0.17-0.93  0.71 0.18 
SJC, swollen joint count; TJC ,tender joint count; ESR, erythrocyte sedimentation rate; VASGH, visual-analogue scale of 
general health; DAS28, disease activity score 28 . 
 
 
Environmental and genomic correlation 
The analysis of the environmental and genomic correlation was performed to assess whether the 
correlation seen between the traits is having environmental or genomic origin.  
Environmental correlations of single outcomes of TNFi therapy generated in bivariate analysis are 
presented in the Table 3. There was a moderate to high positive phenotypic correlation between changes 
in separate DAS28 components. The range for the environmental correlations among changes in separate 
components of DAS28 ranged from 0.09 (between ΔTJC and ΔESR) to 0.6 (between ΔTJC and 
ΔVASGH). 
For change in separate DAS28 components (ΔSJC, ΔTJC, ΔESR and ΔVASGH), there was a positive 
genomic correlation among them, ranging from 0.49 (between ΔSJC and ΔTJC) to 0.23 (between ΔTJC 
and ΔVASGH)  (Table 3). The genetic correlations of each of the changes in separate DAS28 components 
with change in DAS28 were found to be negative, ranging from -0.68 to -0.5 (Table 3); Genomic 
correlations of change in DAS28 with changes in each of its components are indicating what proportion of 
genomic variance in ΔDAS28 is contributed by change in each of DAS28 components; so it is a way to 
measure how strongly each of the separate components contributes to the genetic "make-up" of ΔDAS28.  
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Table 3: Environmental (below diagonal) and genomic correlation (above diagonal) for 
individual traits in a bivariate analysis  
 
ΔSJC ΔTJC ΔESR ΔVASGH ΔDAS28 
ΔSJC 
 
0.49±0.22 0.33±0.24 0.43±0.26 -0.68±0.09 
ΔTJC 0.35±0.29 
 
0.25±0.28 0.23±0.33 -0.65±0.29 
ΔESR 0.10±0.20 0.09±0.16  0.38±0.30 -0.58±0.27 
ΔVASGH 0.20±0.24 0.60±0.24 0.18±0.14  -0.51±0.28 
ΔDAS28 -0.42±0.28 -0.67±0.21 -0.46±0.17 -0.65±0.18  
Numbers are depicted as value ± posterior standard deviation. 
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Multivariate vs univariate GWASs 
488,254 SNPs were tested for association with ΔDAS28, ΔSJC, ΔTJC, ΔESR and ΔVASGH as outcomes 
in univariate analysis. A multivariate GWAS on change in separate DAS28 components was also 
conducted. Quantile-Quantile (Q-Q) plots of GWASs are presented in the Figure 1. Visual inspection of 
inflation of the Q-Q plots is indicating that the multivariate approach (CCA) is not generating excess of low 
P values as compared to an univariate analysis of ΔDAS28. The biggest inflation of P values was observed 
for the ΔSJC univariate GWAS; however, permutation analysis indicated that this inflation is not 
significantly different from the null expectation (P=0.09).  
           
A B C
D E F
ΔDAS28 CCA ΔSJC
ΔTJC ΔESR ΔVASGH
 
Figure 1: Quantile-Quantile (Q-Q) plots for the GWASs. Q-Q plots for the GWAS of (A) change in DAS28, 
(B) multivariate analysis (CCA), (C) change in SJC, (D) change in TJC, (E) change in ESR, (F) change in 
VASGH after 14 weeks of TNFi therapy. 
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Discussion 
Pharmacogenetic studies of TNFi response in patients with RA have relied on composite measures such 
as DAS28 as outcome of the TNFi therapy [174]. This is the first study to date that analyzed the changes in 
the separate components of DAS28 after fourteen weeks of TNFi therapy individually, comparing it with 
both change in DAS28 and multivariate approach that jointly analyses changes in separate components. 
Furthermore, we presented the estimates of heritability for the total amount of additive genetic information 
contained in common SNPs as well as estimates of correlation of the different outcomes of TNFi therapy in 
RA patients of Dutch descent. Accurate measures of heritability are required to understand the basis of 
drug treatment response, and the results presented in this study might serve as a basis for other 
researchers to optimize designs of future studies for identifying additional genetic contributions to TNFi 
pharmacogenetics. 
The fraction of the heritability explained by SNPs was estimated using two different approaches that both 
utilize linear mixed-effect model framework [402, 404]. Both approaches generated similar patterns and 
comparable results for the heritability estimates of single traits. We found that a large proportion of 
variation in ΔSJC can be attributed to common SNPs (hgbayz
2=0.76 and hgGCTA
2=0.87); and estimated 
genomic heritability for ΔTJC was also high (hgbayz
2=0.62 and hgGCTA
2=0.82). On the other hand, our 
results are suggesting that common SNPs have a little (if any) effect on the variation seen in the ΔESR and 
ΔVASGH. For ΔDAS28, estimated proportion of the variation explained by common SNPs is in between 
those seen for joint counts and ΔESR and ΔVASGH. This is not surprising giving the fact that DAS28 is 
composed out these individual measurements. Our results suggest that, as variation seen in changes in 
both SJC and TJC after fourteen weeks of therapy have a sizable heritable component, these represent the 
most suitable outcomes for genetic association studies of TNFi response in patients with RA.     
 
The analysis of environmental and genotypic correlation revealed a positive genetic correlation between 
changes in all individual components of DAS28, ranging from 0.23 (between ΔTJC and ΔVASGH) to 0.49 
(between ΔSJC and ΔTJC), suggesting that changes in swollen and tender joint counts might have a 
common genetic background. Similarly, the estimates for environmental correlation between all of the 
DAS28 components were positive. The estimates for environmental correlation were similar or smaller 
than estimates of genomic correlation for most of the traits, with the marked exception of correlation seen 
between ΔTJC and ΔVASGH. The estimated environmental correlation of these two traits (0.6) was higher 
than the estimate for genetic correlation for the two (0.23), suggesting that most of the covariation may be 
due to non-SNP effects (environmental or other genetic or non-genetic factors). It should be emphasized 
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that the variance was large for all reported estimates and greater statistical power is needed to replicate 
these trends.  
 
We also conducted univariate GWASs using change in both DAS28 and each of its separate components 
as outcomes and compared these results with those yielded with multivariate approach, which included all 
of the DAS28 separate components. The results of multivariate approach were comparable to the 
univariate analysis of ΔDAS28 in that no genome-wide significant associations were identified.  
The findings presented in this study, may serve a useful purpose in the future design of pharmacogenetic 
studies of TNFi response in patients with RA. The composite indices, such as DAS28, are clearly efficient 
in monitoring the effects of the treatment in patients with RA in a clinical setting as they give a 
comprehensive view of the patients' response [385, 386]. However, our results are suggests that disease 
activity score may not be the most suitable outcome for the genetic association studies, as ΔDAS28 is not 
as heritable as ΔSJC and ΔTJC. Furthermore, our data suggest that most of the variation seen in changes 
in joint counts can be attributed to common SNPs. This can have a substantial influence on clinical 
decision making, as the number of SJC and TJC is regarded as the most specific measure of patient 
assessment in usual clinical care [407] and the most important measure for RA clinical trials to 
distinguish active from control trials [408]. Identification of genetic markers that could predict the change 
in joint counts following TNFi therapy could help to tailor the treatment to individual patient and better 
understand the mechanisms underlying the effects of TNFi therapy on pathophysiological changes that are 
taking place in joints of patients with RA.    
In summary, this is the first study to report measures of heritability of both ΔDAS28, and changes in its 
separate components; together with estimates for their genetic and environmental correlations.  In this 
report we used different methodological strategies to define the most suitable outcome of the 
pharmacogenetic studies of TNFi treatment in patients with RA. We provided evidence that common SNPs 
explain large proportions of the phenotypic variation seen in change in joint counts due to TNFi therapy, 
particularly the SJC. Future studies with greater power will provide better accuracy for the estimates 
presented here, and a further validation of our findings in an independent cohort is required. 
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Chapter 7 
GENERAL DISCUSSION 
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Scope of thesis  
The goal of personalized medicine is to use traditional, as well as emerging concepts of the genetic and 
environmental basis of disease, to allow prediction about individuals' susceptibility of developing disease, 
disease prognosis and response to treatment. The clinical response to prescribed drugs is often not 
consistent across individual patients, and this variation is a prominent clinical problem, ranging from a 
lack of therapeutic effect to serious adverse reactions to drug in use. While clinical variables such as the 
disease severity, organ function, gender, age, co-medication and smoking status can be important 
determinants of drug response, genetic variability in genes encoding proteins involved in drug 
metabolism, disposition and/or mechanism of action are potentially even more important cause of 
differential response to therapeutic drugs [154-156]. Therefore, pharmacogenetics and 
pharmacogenomics hold the promise for the ultimate aim of personalized medicine by studying the 
association between a clinical responses to drugs and patients' genetic makeup. However, the relevance of 
pharmacogenetics lies beyond predicting the efficacy of treatment. Pharmacogenetic research is an 
effective tool to understand the fundamental biology of complex traits, such as rheumatoid arthritis (RA), 
which are recognized as clinical syndromes spanning several disease subsets, rather than a discrete 
conditions [28]. Pharmacogenetic studies, together with genetic association studies of disease 
susceptibility, are invaluable instruments for decomposing these disease subsets and better 
understanding of the critical determinants of a disease, ultimately leading to more effective treatment 
strategies and better clinical care. In addition, optimizing therapeutic strategies using genetics may result 
in a reduction of the utilization of health care resources and subsequently disease related costs.  
The goal of this thesis was to contribute to the knowledge of the genetic susceptibility to RA and the 
treatment response to tumor necrosis factor inhibitors (TNFi) in these patients. To investigate this, we 
used both hypothesis-driven and non-hypothesis-driven approaches. We mainly focused on treatment 
outcome; however we also studied disease susceptibility as literature indicates that disease susceptibility 
genes might also predict treatment outcome [307, 308]. Besides, the target of TNFi therapy, tumour 
necrosis factor (TNF), plays a pivotal role in the pathogenesis of RA, again indicating that the same genes 
might be involved in susceptibility as well as treatment outcome [160, 291].  
In this chapter, we first discuss our most important findings. Second, we describe the strengths and 
limitations of studies presented in this thesis and finally, we elaborate on implications for clinical practice 
and future research perspective.      
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Main findings 
The hypothesis-driven approach is presented in the first part of this thesis, where we explored whether a 
deletion in the region of the LCE3C and LCE3B genes is associated with RA susceptibility (Chapter 2). We 
detected a suggestive association in the Dutch cohort (P=0.093). Nevertheless, meta-analysis of our data 
with previously published Spanish and Chinese data sets [177, 178] showed a significant association, and 
resulted in lower P values, lower odds ratio (OR) and a smaller confidence interval (CI) than without our 
dataset, nicely illustrating the importance of replication of genetic findings in independent cohorts and 
emphasising the usefulness of combining the results across different cohorts in meta-analysis. Also, we 
found no association of rs4112788, a SNP that is in full LD with the LCE3C_LCE3B-del, with TNFi 
treatment response in the Dutch cohort (data not shown).      
In Chapter 3, we described the limited amount of promising findings within the field of pharmacogenetics 
of disease-modifying anti-rheumatic drugs in patients with RA. Studies conducted at that time mostly 
included single SNPs in candidate genes, small sample sizes, conventional statistics and complex 
disease scores as outcome for TNFi therapy. In this thesis, we tackled these problems by performing large 
scale non-hypothesis driven approaches and using more homogeneous outcomes for TNFi therapy. 
The results of the non-hypothesis-driven approach are presented in the second part of this thesis. 
Genome-wide association studies (GWASs) in RA patients treated with TNFi were performed to further 
contribute to the knowledge about the genetic background of the response to TNFi treatment, and 
innovative analysis methods were applied to investigate the different aspects of the TNFi response and 
pharmacogenetics of TNFi (Chapter 4, Chapter 5 and Chapter 6).  
Our initial GWAS, presented in Chapter 4, indicated that there are no common variants with large effect 
size influencing the change in disease activity score 28 (DAS28) in patients with RA treated with TNFi. 
Another conclusion drawn from this study was that response to TNFi is a complex phenotype with a 
genetic architecture resembling that seen in other complex traits. However, the results of the pathway 
analysis showed an overrepresentation of genes involved in biological processes underlying inflammatory 
response, suggesting that common variation in genes coding for multiple targets of TNFi within the 
inflammatory system are involved in the differential response to these drugs. Furthermore, we used the 
change in pain as an alternative phenotype in the GWAS study. We utilize this biologically meaningful 
component of TNFi response as a better proxy to the underlying genetic background (Chapter 5). Although 
this study revealed no genome-wide significant findings, the results indicated strong involvement of genes 
with biological functions highly relevant for pain sensitivity and transduction. The findings of this study are 
highlighting the importance of using relevant endophenotypes, in an attempt to better understand and 
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decipher the complex phenotypes, such as response to TNFi therapy. Finally, in Chapter 6, we investigate 
the components of DAS28 as alternative phenotypes of TNFi therapy outcome, showing that multiple SNP 
effects together explain a sizable proportion of the variation seen in TNFi induced change in swollen and 
tender joint counts in patients with RA, while the proportion of variance in TNFi induced changes in 
erythrocyte sedimentation rate (ESR) and the patient's general health (VAS-GH) that can be attributed to 
common SNP is low, if existing at all. We also show that the heritability of the change in DAS28 lies 
between these two extremes, which is not surprising since DAS28 is composed of these components. 
From a clinical and genetic point of view, there is little value in GWAS of outcomes in which most of the 
variation is coming from environmental and other non-SNP effects; therefore, based on our study designs 
for future TNFi pharmacogenetic studies in patients with RA might be optimized. 
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Strengths and limitations of the studies presented in this thesis             
To draw firm conclusions from an association study, it is critical to use well characterized and large 
patient cohorts, with as little heterogeneity regarding subject ascertainment and assessment as possible. 
The first strength of our study was the availability of such patient collection. The Dutch patient cohort used 
for our pharmacogenetic studies was derived from the DREAM (www.dreamregistry.nl) and ApotheekZorg 
registries, which are collections with similar inclusion criteria. Besides, various disease characteristics are 
collected, such as gender, age, disease activity, response to anti-TNF medication, co-medication, and 
serological markers (rheumatoid factor and anti-CCP). In our analysis these parameters were interrogated, 
but they show no correlation with the response to TNFi therapy.  
Another key component of a well-designed genetic association study is the availability of replication 
samples, and the validation of observed associations in independent studies, as well as the application of 
meta-analysis to boost statistical power by combining results across multiple samples of individuals. The 
validation of initial findings in genetic association studies is essential, as these may overestimate the 
variant's effects due to the "winner's curse" phenomenon. Initially reported significant findings are likely to 
exhibit some regression-to-the-mean upon further testing. This is nicely illustrated in our meta-analysis of 
the deletion in LCE3C and LCE3B genes, in which a large Dutch cohort is added to the two previously 
published studies leading to more accurate prediction of variant's effect size. The independent collections 
were also available for validation of the results of our GWAS of TNFi response in patients with RA. Meta-
analysis approaches were applied to combine the results from different GWASs of TNFi response, as 
aggregation of evidence from multiple cohorts is required to obtain the statistical power necessary to 
detect small effects. The reliability of meta-analysis is affected by the reliability of the included data. And 
although all available precautionary measures were taken to avoid bias (e. g., the uniform quality control 
criteria were applied across different collections, population outliers were removed and analyses were 
corrected for principal components to avoid population stratification, etc.), the replication cohorts for our 
GWASs, as well as meta-analyses, included international patients collections that showed considerable 
heterogeneity when compared with our cohort. Combining the results across such different cohorts, with 
effect estimates varying among the studies, can lead to false negative results. On the other hand, findings 
from the recent GWAS in the TNFi response in patients in RA are suggesting that genetic control of 
treatment response may be different for two separate TNFi classes (the soluble receptor drug, etanercept 
versus two monoclonal antibody drugs, infliximab and adalimumab) [401], which is an additional source 
of heterogeneity that was not taken into account in our analysis.     
121 
The non-hypothesis driven GWAS approach serves as a good foundation experiment to either identify 
causative/predictive genetic markers for a given trait or provide insight into the genetic architecture of the 
trait of interest. Since 2007, GWAS have increasingly been applied in the field of pharmacogenetics. In the 
initial efforts, GWAS approaches have shown to be remarkably successful in identifying variants 
associated with a number of pharmacogenetic traits [409]. Most of these initial studies included a small 
number of cases, and were still able to detect genome-wide significant associations, suggesting that at 
least some pharmacogenetic effects tend to be larger and involve fewer genes than those detected in 
GWAS for complex diseases. These results supported the long-lasting theory that the pharmacogenetic 
variants will often have little phenotypic effect before the administration of the drug [410], escaping the 
attention of natural selection. Unfortunately, as more pharmacogenetic GWAS are performed, it seems 
obvious that these results are not universal and are reflecting the low-hanging fruits [411]. In light of our 
results, we can conclude that there are no genetic markers with high effect sizes influencing the response 
to TNFi therapy, and that the TNFi response is a complex phenomenon. The detection of SNPs with 
modest and small effect sizes (OR < 1.5) at a stringent level of statistical significance in a GWAS study 
requires recruitment of extremely large sample sizes [319], and the patient populations used in our 
studies might have been vastly underpowered to reveal anything but SNPs with large effects. Another 
interesting observation is that none of the top scoring findings from our GWAS could be replicated in other 
populations. This could be a result of the low statistical power, as underpowered studies have not only a 
reduced chance of detecting a true effect, but they also reduce the likelihood that a statistically significant 
result reflects a true effect [412]. On the other hand, it is tempting to speculate that these findings could 
represent population specific synthetic associations with single or multiple rare causal variants, as 
suggested by Dickson et al. [413].  
Additional limitation of GWAS is that contemporary genotyping platforms cover only common SNPs. The 
debate about the genetic architecture of common traits is ongoing. Although the simulation and empirical 
analysis of GWA data are suggesting that complex traits, such as RA, are highly polygenic and that 
additional common alleles of small effect sizes remain to be discovered [62], rare and low-frequency 
variants together with CNVs and other structural variants are likely to contribute to overall heritability. The 
extent of this contribution is, however, debatable, as available data, which is still limited, suggest that the 
relative contribution of these variants to common phenotypes will be modest at best [65-71, 76-81]. 
Therefore, the studies of these variants are required in order to completely understand the genetic basis of 
complex phenotypes, such as common diseases and treatment response; as indicated by our study of role 
of common deletion in LCE3C and LCE3B genes in RA susceptibility. It is important to notice, though, that 
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most of the studies of role of the rare and structural variants in complex traits reported to date, were 
candidate gene studies. This is a good and affordable method, however, it can create misleading 
conclusions as investigators might have simply picked the wrong genes. Thus, large-scale whole-genome 
sequencing studies will ultimately be required to empirically test the contribution of these variants to 
common phenotypes.  
Another consideration of importance for any pharmacogenetic study design is the definition of a solid 
outcome. The outcome used in the study may influence the power to detect a pharmacogenetic 
interaction, but at the same time, it can affect the implications of the study findings. RA is a very 
heterogeneous disease, with many factors known to play a role in disease control. Complex indices, such 
as RA disease activity scores, have been commonly used as a outcome measures in pharmacogenetic 
studies of TNFi response; however, since they are composed of several parameters, it is unlikely that they 
represent the most optimal outcome for genetic studies. Within the studies described in this thesis we 
showed that some disease outcomes (e.g. pain, ΔSJC, ΔTJC) are more suitable for future studies in the 
field of TNFi pharmacogenetics. Change in pain due to TNFi therapy  is a particularly interesting outcome, 
since patients rate pain relief as one of their highest priorities [83, 84], and it is a more genetically 
homogeneous measurement than disease activity score. Nevertheless, our GWAS analysis on pain 
reduction in TNFi treated patients with RA failed to discover any genome-wide significant findings, 
indicating that this outcome is very likely to be under polygenic control and that replications in large 
sample collections will be required to reveal the true associations.  
Furthermore, all studies reported in this thesis used the cross-sectional analysis, also called the snapshot 
approach, examining only one time point (fourteen weeks of the therapy) during TNFi treatment. This 
approach suffers from several methodological weaknesses. First, it is less informative and it may not 
reflect the true nature of the response over the whole treatment phase. This is particularly interesting in the 
case of TNFi response in patients with RA, since clinical research already indicated that non-response to 
TNFi agents can be divided into two categories: primary non-response, in which the failure of the drug to 
benefit the patient is evident early in the course of the therapy, and secondary non-response, that develops 
over time. Our studies focused on the issue of the primary non-response, neglecting the secondary non-
response. However, it is important to notice that this could be also viewed as a study strength, as studies 
were focusing on more homogeneous group of patients. From a clinical point of view, there is also more 
value in determining genetic markers of primary non-response alone, as secondary non-responders can 
still benefit from TNFi therapy until the non-response is developed.  Furthermore, we only evaluated 
patients that were still available at the analysed time point, ignoring dropouts and missing data. Quite 
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often, missing data is not missing at random and could be related to primary outcome (e. g., intolerance 
or side effects). Future pharmacogenetic studies of TNFi treatment response should preferably evaluate the 
treatment response in a longitudinal way, including the data from multiple time points during the treatment 
course. This approach will generate information that has greater clinical relevance because it will predict 
the long-term response characteristics and will reduce the risk of both false-positive and -negative 
findings.    
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Future research perspective 
Pharmacogenetic studies reported so far have only scratched the surface of the genetic complexity 
underlying the mechanism of TNFi response. Based on the studies presented in this thesis we can 
conclude with that pharmacogenetic predictors of TNFi response are highly polygenic, with possible gene-
gene and gene-environment interactions. A focus of genetic studies is slowly shifting from studies of 
individual markers in GWAS towards the polygenic score analysis, which summarizes genetic effects 
among an ensemble of markers [414]. Although polygenic scores still have more utility for association 
testing, combining genomic scores derived from large sample sizes with environmental covariates into a 
composite analysis should, in theory, ultimately lead to the development of accurate prediction models. It 
is becoming increasingly apparent that these composite analyses should be more appropriate for analysis 
of most pharmacogenetic traits then studies of single variants. However, the complexity of the underlying 
genetic architecture undermines these attempts, and larger patient cohorts and dense genetic information 
is required for such interaction studies. A more realistic perspective on the role of RA pharmacogenetics 
in patients care is that it provides the opportunity to fully understand the disease pathophysiology and 
mechanism of action of the specific drug, which holds an enormous potential for novel therapeutic 
strategies, and decomposing the disease subsets. This could result in more targeted treatment strategies 
for subcategories of the patients. Using different outcome measures can greatly aid this process by 
pinpointing specific components of the underlying biology of the response, as illustrated in studies of 
change in pain and separate components of DAS28 presented in this thesis. It is also expected that the 
effect sizes of genetic loci contributing to outcome measures that bear a closer relationship to the 
biological processes are larger than those contributing to the commonly used, complex disease activity 
scores. We suggest that using alternative outcomes, such as change in pain and joint counts may facilitate 
the discovery of genetic variants underlying the differential response to TNFi therapy. Ideally, these future 
studies should also analyze the response to specific TNFi agents (five are available at the moment), as 
these may differ in their pharmacokinetic and pharmacodinamic properties, and current sample sizes are 
underpowered for such stratification. Finally, functional studies will be necessary to further enhance the 
genetic knowledge and prove if identified variants indeed have an effect on the gene. These findings will 
provide a valuable insight in the processes underlying non-response and disease susceptibility and will 
speed uptake of this knowledge in a clinical setting. The cohorts of patients with RA treated with TNFi 
medication included in pharmacogenetic studies have increased over the last years and will keep on 
expanding; still, larger, homogeneous and well-characterized collections of RA patients with prolonged 
follow-up are absolutely necessary in order to tackle the question of TNFi non-response.   
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In addition, the application of whole genome sequencing could lead to rare variant discovery and has the 
potential to yield more obviously functional variants with larger effect sizes.  The effect sizes of these rare 
variants is also expected to be larger, as due to the young age of most rare variants purifying selection 
hasn‟t had much opportunity to act and remove them from the population. Furthermore, there is a 
reasonable hope that a combination of different “omics” technologies might also benefit the 
pharmacogenetic research. The operation of biological networks is not only affected by variation in coding 
sequence but also by stochastic processes and transient responses to external signals at both RNA and 
protein level [415]. Integration of this data was shown to be useful in interpretation of healthy and 
diseased states, and can potentially help in the diagnostics, monitoring and treatment [416]. However, for 
successful application of large genome-wide screens on DNA, RNA, protein and metabolite levels large 
well-characterized cohorts of patients are of utmost importance. Therefore, multicenter collaborations 
should concentrate on collecting electronic medical and health records that could compare the data on 
treatment outcome in thousands of patients using a real clinical setting, including the integration of 
genomic and multi-omics data and making this data available for public analysis. First steps in such 
crowd-sourcing attempts are already being taken in the field of RA [417], and although this particular 
attempt is limited on gathering the information on the DNA level alone, it represents a great initiative that 
should be strongly encouraged in the field of complex genetics.             
 
In the last decade remarkable progress has been made in the field of human genetics. Although the field of 
pharmacogenetics has been lagging behind the genetic studies of disease susceptibility, its relevance is 
being increasingly recognized as it could not only help discriminating responders and non-responders to 
currently available therapies but will also help us understand the basic human physiology. Bearing in mind 
the unprecedented pace at which the field of genetics is evolving, and with the increasing affordability of 
the whole-genome sequencing technologies it is believed that the full scope of the influence of genetic 
factors on susceptibility to complex traits and treatment response will be uncovered within next decades. 
Personalized medicine will continue to be in transition toward whole-genome sequencing for the 
foreseeable future, and as next-generation sequencing technologies are already being used for diagnostic 
testing of rare conditions, this will greatly facilitate the identification of genetic variants involved in 
complex traits but also the implementation of these findings in the clinical setting. Genetic profiling, with 
inclusion of information on the other risk factors, could ultimately lead to the development of the 
prediction models that will allow the application of personalized medicine.       
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SUMMARY 
Rheumatoid arthritis (RA) is a common, chronic, inflammatory disease characterized by synovial 
inflammation that, if left untreated, may lead to severe joint destruction and disability. The specific cause 
of RA remains obscure, however, it is generally accepted that a combination of environmental and genetic 
factors play a role in onset and severity of the disease. RA cannot be cured, and therapeutic intervention is 
aiming at reducing the symptoms of the disease and minimizing joint damage. The blockade of tumor 
necrosis factor (TNF) has proven to be very effective in controlling clinical signs of RA and preventing 
further structural damage. However, a substantial proportion (~30%) of patients with RA treated with TNF-
blocking agents (TNFi) fail to show any significant clinical improvement. Non-response, coupled with high 
costs, occurrence of toxicities and possible unintentional concomitant immune suppression associated 
with TNFi use, has driven the search for genetic markers predicting the outcome of the TNFi therapy, since 
these could facilitate the choice for the most suitable treatment regimen for an individual patient in daily 
clinical practice.  
The main goal of this thesis is the identification of genetic predictors of TNFi treatment outcome in 
patients with RA. Since TNF cytokine plays a crucial role in initiation of inflammatory cascade involved in 
pathogenesis of RA, it can be assumed that genetic loci involved in TNFi treatment response overlap with 
disease susceptibility loci. Therefore, we also aimed at exploring the role of genetic variants in the onset 
of the disease.  
This thesis consists of two parts. The first part (chapter 2) focuses on studying the role of copy number 
variants in RA in a hypothesis driven manner, while the second part (chapters 4 to 6) of this thesis 
concentrates on the application of hypothesis generating, genome-wide association studies (GWAS), to 
investigate genetic markers of TNFi response in patients with RA. The cohort used to study RA 
susceptibility included patients from the Dutch Rheumatoid Arthritis Monitoring (DREAM), while the 
controls were participating in the Nijmegen Biomedical Study. The studies of TNFi response included 
patients from both DREAM and Apotheekzorg registries, as a discovery cohort; while replication and 
combined analysis included samples gathered through collaboration with complementary international 
cohorts.   
Following a general introduction, in chapter 2, the role of a deletion of the Late Cornified Envelope (LCE) 
3B and 3C genes (LCE3C_LCE3B-del), a known psoriasis risk factor, in RA susceptibility is investigated. 
Recently, two studies in Spanish and Chinese population pointed to an association of this deletion and RA 
risk, and we aimed at replicating these findings in a Dutch population. A total of 1039 RA cases and 759 
controls were investigated as a part of Dutch collection. Subsequently, a meta-analysis was performed 
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combining our data with the Spanish and Chinese datasets, resulting in an analysis including 2466 RA 
cases and 2438 controls. No significant association of LCE3C_LCE3B-del with RA risk was observed in 
the Dutch cohort. However, the results of a meta-analysis, confirmed a significant association and yielded 
more accurate estimate of effect size for this variant. These results are suggesting that LCE3C_LCE3B-del 
is a common risk factor for (auto)immune diseases. 
Chapter 3 gives an overview of the current literature concerning pharmacogenetics of disease-modifying 
anti-rheumatic drugs, including TNFi, in patients with RA and discusses different strategies and 
perspectives for further studies in the field.   
The results of the non-hypothesis-driven approach are presented in the second part of this thesis. In 
chapter 4 to 6, the response to TNF blocking agents in patients with RA was investigated using genome-
wide association studies (GWASs) and innovative analysis methods were utilized to further analyse the 
different aspects of the TNFi response.  
In chapter 4, a multi-stage, genome-wide association study was performed including 882 TNFi treated 
patients with RA in the discovery phase. The response was defined as a changes in the Disease Activity 
Score in 28 joints (DAS28) after fourteen weeks of treatment and markers with p<10-3 were selected for 
replication in 1,821 RA patients from three independent cohorts. Eight genetic loci improved P value in 
the overall meta-analysis compared with the discovery stage, three of which (rs1568885, rs1813443 and 
rs4411591) showed directional consistency over all four cohorts studied. However, none of the genetic 
markers reached genome-wide significance, indicating that there are no common variants with large effect 
size influencing the change in DAS28. Nevertheless, network analysis indicated overrepresentation of 
genes involved in biological processes underlying inflammatory response and cell morphology, implying 
that common variation in genes coding for multiple targets of TNFi within the inflammatory system may be 
involved in the differential response to these drugs. 
Subsequently, in chapter 5, GWAS of pain reduction following TNFi therapy in patients with RA was 
performed, including 508 RA patients treated with TNFi agents from the Netherlands in the discovery 
cohort, and a subsequent meta-analysis combining the results of the initial GWAS study with three 
additional GWASs on a total sample of 1287 patients with RA. Change in pain was used as an alternative 
measure of treatment response, for two reasons. First, pain reduction is rated as a priority of treatment by 
patients, and second, this outcome is more homogenous and closer to the underlying biology of the TNF 
action when compared to complex disease activity scores. Unfortunately, none of the findings reached the 
threshold for genome-wide significance in the discovery cohort or meta-analysis. However, the analyses 
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revealed several candidate genes that are known to be involved in biological functions highly relevant for 
pain sensitivity and transduction; such as the KCNK10 gene, which codes for a protein that belongs to the 
family of potassium channel proteins and the  RET gene, which is known to be involved in neuronal 
processes and nociception.  
Chapter 6 dives deeper into the analyses of different aspects of TNFi response, investigating the 
components of DAS28 as an alternative phenotypes in GWAS of TNFi therapy outcome. Also, the 
estimates of the proportion of variation that can be attributed to common SNPs are provided, for changes 
in both DAS28, which is a complex disease score commonly used to monitor the response, and for the 
changes in measurements from which DAS28 is being calculated: swollen joint cont (SJC), tender joint 
count (TJC), erythrocyte sedimentation rate (ESR), and patient's general health (VASGH). Analysis 
revealed that common SNPs explain a substantial proportion of the variation seen in TNFi induced change 
in SJC and TJC, while the proportion of variance in TNFi induced changes in ESR and VASGH that can be 
caused by common SNPs is low, if existing at all. The heritability estimate of the change in DAS28 was 
found to be between these two extremes. Furthermore, multivariate approach was implemented, in which 
separate DAS28 components are analyzed together in order to examine if this approach yields better 
results as compared to the univariate analysis of ΔDAS28 and changes in its separate components. 
However, it did not generate excess of low P values as compared to an univariate analysis of change in 
DAS28. These results indicated that joint counts may be the most suitable outcome for the study of TNFi 
pharmacogenetics in RA.  
In the general discussion (chapter 7) the main findings of the research presented in this thesis are 
summarized and placed in the broader perspective of pharmacogenetics. Different approaches and 
possible future directions that might aid the discovery of the pharmacogenetic markers  responsible for 
TNFi therapy outcome in patients with RA are also discussed in this chapter. Once these pharmacogenetic 
markers are identified and validated, they may be of enormous clinical benefit by both enabling 
personalized treatment in patients with RA and facilitating the identification of novel therapeutic strategies 
through better understanding basic human physiology.  
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SAMENVATTING 
Reumatoïde artritis (RA) is een veel voorkomende, chronische, inflammatoire ziekte die wordt gekenmerkt 
door synoviale ontsteking die, indien onbehandeld, kan leiden tot ernstige gewrichtsschade en invaliditeit. 
De specifieke oorzaak van RA blijft onduidelijk, echter wordt algemeen aangenomen dat een combinatie 
van omgevingsfactoren en genetische factoren een rol in het beginstadium en ernst van de ziekte. RA kan 
niet worden genezen en therapeutische interventie is gericht op het verminderen van de symptomen van 
de ziekte en het minimaliseren van gewrichtsschade. De blokkade van tumornecrosefactor (TNF) heeft 
bewezen zeer effectief te zijn bij het beheersen van klinische symptomen van RA en het voorkomen van 
verdere structurele schade. Een aanzienlijk deel (~ 30%) van de met TNF-remmers (TNFi) behandelde RA 
patiënten laat echter geen significante klinische verbetering zien. Het optreden van non-respons, in 
combinatie met hoge kosten, toxiciteit en mogelijke onbedoelde gelijktijdige immunosuppressie 
verbonden aan TNFi gebruik, is aanleiding geweest voor de zoektocht naar genetische merkers die de 
uitkomst van de therapie TNFi kunnen voorspellen. Deze merkers kunnen de keuze voor de meest 
geschikte behandelingsregime vergemakkelijken voor een individuele patiënt in de dagelijkse klinische 
praktijk. 
Het belangrijkste doel van dit proefschrift is de identificatie van genetische voorspellers van TNFi 
behandelingsresultaat bij patiënten met RA. Omdat het TNF cytokine een cruciale rol speelt bij de initiatie 
van inflammatoire cascade die betrokken zijn bij de pathogenese van RA, kan worden aangenomen dat 
genetische loci die betrokken zijn bij TNFi behandelingsrespons overlappen met ziektegevoeligheid loci. 
Daarom hebben we ons ook gericht op het onderzoeken van de rol van genetische variaties in het begin 
van de ziekte. 
 
Dit proefschrift bestaat uit twee delen. Het eerste deel (hoofdstuk 2) richt zich op het bestuderen van de rol 
van de kopie aantal varianten in RA in een hypothese-gedreven manier, terwijl het tweede deel 
(hoofdstukken 4-6) van dit proefschrift zich richt op de toepassing van de hypothese genererende, 
genoom-brede associatie (GWAS), om genetische merkers van TNFi respons te onderzoeken bij patiënten 
met RA. Het gebruikte cohort  om RA gevoeligheid te onderzoeken, omvatte patiënten uit de Nederlandse 
Reumatoïde Artritis Monitoring (DREAM), terwijl de controles deelnamen aan de Nijmeegse Biomedische 
Studie. Voor de studies van TNFi reactie includeerden we patiënten uit zowel DREAM en ApotheekZorg 
registers, als een ontdekkingscohort, terwijl de replicatie en gecombineerde analyse monsters verzameld 
door middel van samenwerking met complementaire internationale cohorten omvatte. 
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Na een algemene inleiding, wordt in hoofdstuk 2 de rol van een deletie van de Late Cornified Envelope 
(LCE) 3B en 3C genen (LCE3C_LCE3B-del), een bekende psoriasis risicofactor, in gevoeligheid voor RA 
onderzocht. Onlangs wezen twee studies in een Spaanse en Chinese populatie naar een associatie van 
deze deletie en RA risico. Getracht werd deze bevindingen in een Nederlandse populatie te repliceren. 
Hiervoor werden 1039 RA patiënten en 759 controles onderzocht. Vervolgens werd een meta-analyse 
uitgevoerd waarbij onze data werd gecombineerd met de Spaanse en Chinese datasets, wat resulteert in 
een analyse van 2466 RA patiënten en 2438 controles. In het Nederlandse cohort werd geen significante 
associatie van LCE3C_LCE3B-del met RA risico waargenomen. De resultaten van de meta-analyse 
bevestigden echter wel een significante associatie en leverde een nauwkeuriger schatting op van de 
omvang van het effect van deze variant. Deze resultaten suggereren dat LCE3C_LCE3B-del een veel 
voorkomende risicofactor voor (auto) immuunziekten is. 
Hoofdstuk 3 geeft een overzicht van de huidige literatuur over farmacogenetica van disease-modifying 
anti-reumatische geneesmiddelen, waaronder TNFi, bij patiënten met RA en bespreekt verschillende 
strategieën en perspectieven voor verdere studies in het veld. 
De resultaten van de niet hypothese-gedreven aanpak worden gepresenteerd in het tweede deel van dit 
proefschrift. In hoofdstuk 4-6 werd de respons op TNF-remmers bij patiënten met RA onderzocht met 
behulp van genoom-brede associatie studies (GWASs). Tevens werden vernieuwende analyse methoden 
gebruikt om de verschillende aspecten van de TNFi respons verder te analyseren. 
In hoofdstuk 4 werd een multi-stage GWAS uitgevoerd onder 882 TNFi behandelde patiënten met RA in de 
ontdekkingsfase. De respons werd gedefinieerd als een verandering in de Disease Activity Score in 28 
gewrichten (DAS28) na veertien weken van de behandeling en markers met P<10-3 werden geselecteerd 
voor replicatie in 1821 RA patiënten uit drie onafhankelijke cohorten. Van acht genetische loci verbeterde 
de P-waarde in de totale meta-analyse vergeleken met de ontdekkingsfase, waarvan er drie (rs1568885, 
rs1813443 en rs4411591) directionele consistentie toonden in alle vier onderzochte cohorten. Geen van 
de genetische merkers bereikte echter genoom-brede significantie, wat aangeeft dat er geen 
gemeenschappelijke varianten een groot effect hebben op de verandering in DAS28. Desalniettemin geeft 
netwerkanalyse oververtegenwoordiging aan van genen betrokken bij biologische processen onderliggend 
aan ontstekingsreactie en celmorfologie, implicerend dat gemeenschappelijke variatie in genen die 
coderen voor meerdere doelen van TNFi binnen het ontstekingssysteem betrokken kunnen zijn bij de 
differentiële respons op deze geneesmiddelen. 
Vervolgens wordt in hoofdstuk 5 GWAS van pijnvermindering volgend op TNFi therapie bij patiënten met 
RA uitgevoerd, met inbegrip van 508 Nederlandse RA-patiënten die behandeld werden met TNFi middelen 
155 
in het ontdekkingscohort, en ook een latere meta-analyse die de resultaten van de eerste GWAS studie met 
drie extra GWASs combineert tot een totale omvang van 1287 patiënten met RA. Verandering in pijn werd 
gebruikt als alternatief voor de behandelingsrespons, om twee redenen. Ten eerste wordt pijnverlichting 
door patiënten beoordeeld als een prioriteit van behandeling; ten tweede is deze uitkomst homogener en 
ligt deze dichter bij de onderliggende biologie van de TNF werking in vergelijking met complexe 
ziekteactiviteit scores. Helaas bereikt geen van de bevindingen genoom-brede significantie in het 
ontdekkingscohort voor de meta-analyse. De analyses toonden daarentegen wel verschillende kandidaat-
genen (waarvan bekend is dat ze betrokken zijn bij biologische functies) die zeer relevant zijn voor 
pijngevoeligheid en transductie, zoals het KCNK10 gen dat codeert voor een eiwit dat behoort tot de 
familie van kaliumkanaal eiwitten, en het RET gen waarvan bekend is dat het betrokken is bij neuronale 
processen en nociceptie. 
Hoofdstuk 6 duikt dieper in de analyses van verschillende aspecten van TNFi respons, waarbij de 
componenten van DAS28 onderzocht worden als alternatieve fenotypes in GWAS van TNFi therapie 
uitkomst. Ook worden de schattingen van de hoeveelheid variatie die kan worden toegeschreven aan 
gemeenschappelijke SNPs geleverd: zowel voor veranderingen in DAS28, (een complexe ziekte score die 
vaak gebruikt wordt om de reactie van de patiënt te monitoren) als voor de veranderingen in de metingen 
waaruit DAS28 wordt berekend (het aantal gezwollen gewrichten (SJC), het aantal gevoelige gewrichten 
(TJC), bezinking (ESR), en de algemene gezondheid van de patiënt (VASGH)). Analyse toonde aan dat 
vaak voorkomende SNPs een groot deel van de variatie voor TNFi-geïnduceerde verandering in SJC en 
TJC verklaren, terwijl het aandeel van de variantie in TNFi-geïnduceerde veranderingen in ESR en VASGH 
dat kan worden veroorzaakt door vaak voorkomende SNPs laag tot niet aanwezig is. De schatting van de 
erfelijkheid van de verandering in DAS28 bleek tussen deze twee uitersten te liggen. Daarnaast werd 
multivariate benadering toegepast waarbij afzonderlijke componenten van DAS28 samen worden 
geanalyseerd om te onderzoeken of deze aanpak betere resultaten levert in vergelijking met de univariate 
ΔDAS28 analyse en veranderingen in de afzonderlijke componenten. Deze aanpak wist desondanks niet 
meer lage P-waarden te genereren in vergelijking met een univariate analyse van de verandering in 
DAS28. Deze resultaten gaven aan dat gewrichten (SJC en TJC) de meest geschikte indicatoren voor de 
studie van TNFi farmacogenetica bij RA kunnen zijn. 
In de algemene discussie (hoofdstuk 7) zijn de belangrijkste bevindingen van de in dit proefschrift 
beschreven onderzoek samengevat en in het bredere perspectief van de farmacogenetica geplaatst. 
Verschillende benaderingen en mogelijke toekomstige richtingen dat de ontdekking van de 
farmacogenetische merkers verantwoordelijk voor TNFi therapie uitkomst bij patiënten met RA zou kunnen 
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helpen. Zodra deze farmacogenetische merkers zijn geïdentificeerd en gevalideerd, kunnen ze van enorm 
klinisch voordeel zijn door zowel gepersonaliseerde behandeling bij patiënten met RA te vergemakkelijken 
als de identificatie van nieuwe therapeutische strategieën te faciliteren door middel van een beter begrip 
van de fundamentele menselijke fysiologie. 
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